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ABSTRACT
Ortiz, Linda Felicitas. The role of aryl hydrocarbon receptor activation on immunoglobulin Asecreting B cell gut homing. Unpublished Master of Science Thesis, University of
Northern Colorado, 2022.
Within the United States, foodborne diseases are estimated to result in more than 100,000
hospitalizations each year with 3,000 fatalities. Acute gastroenteritis impacts more than 1.5
million children each year in the United States. Worldwide, childhood morbidity and mortality
are largely attributed to infectious diarrheal diseases. To combat infection at mucosal surfaces,
immunoglobulin (Ig) A is produced by antibody-secreting B cells to inhibit and neutralize
pathogens and their toxins. B cells are influenced by various extrinsic signals through activation
of the aryl hydrocarbon receptor (AhR). The AhR is a ligand-activated transcription factor that
links diet and environmental factors to intestinal immune function. Recently, some T cells have
been shown to favor migration to the intestines after activation of the AhR in mice. B cell fate
outcomes and antibody secretion are impacted by AhR activation, but it is unknown if B cell
migration is also impacted. We have previously shown a decrease in IgA levels in serum of mice
treated with the prototypic ligand for the AhR, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). In
contrast, fecal IgA levels were unchanged by TCDD treatment. To explain this, we hypothesized
that AhR activation favors migration of plasma cells out of blood-associated lymphoid tissues
and into gut-associated lymphoid tissues through positively regulating the expression of
molecules required for gut-homing. We predicted that the number of IgA-secreting cells in
spleens would be significantly reduced by TCDD exposure in vivo and splenic B cells would
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have increased expression of gut migration markers when exposed to TCDD in vitro. To test this
in vivo, we quantitatively determined IgA-secreting cells in the spleens of cholera toxin
immunized mice. To elucidate the molecular mechanisms by which this differential regulation
occurs in vitro, we exposed splenic CD19+ cells to AhR ligands for 96 hours, followed by flow
cytometric analysis of expression of gut migration molecules. Treatment with TCDD in vivo
significantly reduced the number of IgA-secreting cells contributing to systemic immunity and
reduced the number of cholera toxin-specific IgA-secreting cells contributing to long-term
systemic recall responses. Furthermore, AhR activity in vitro altered the expression of molecules
required for gut-homing, suggesting that AhR activation in vivo positively regulates IgAsecreting cell trafficking to the small intestine. Because the gut contains approximately 80% of
all antibody-secreting cells, secreting large quantities of IgA for defense against pathogenic
infection and maintaining intestinal homeostasis, altering antibody-secreting cell migration is a
promising target for the treatment of autoimmunity and the enhancement of intestinal disease
resistance. The results of these studies fill a gap in knowledge regarding AhR modulation of gut
antibody responses and expand our mechanistic understanding of how AhR activity influences
intestinal disease resistance.
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CHAPTER I
INTRODUCTION
Foodborne Pathogen Defense
As of 2019, foodborne illness data collected nationwide indicates that progress towards
regulating foodborne pathogens has stalled (Tack et al., 2020). Furthermore, more than half of
the cases of foodborne illnesses in the United States are estimated to result from unknown
foodborne agents (Scallan, Griffin, et al., 2011). Our first line of defense against foodborne
pathogens is the gastrointestinal tract. The gastrointestinal tract is comprised of specialized
epithelial cells and humoral components that aid in protection against enteric pathogens and
toxins (Ramanan & Cadwell, 2016). When this barrier is breached, pathogens are detected in the
underlying intestinal lamina propria (LP) which stimulates the innate immune system for defense
(Kinnebrew & Pamer, 2012). Additionally, the gastrointestinal tract contains the largest amount
of immunoglobulin (Ig) A-secreting plasma cells in the body for defense against pathogens and
toxins (Suzuki et al., 2007), these plasma cells (PCs) have been shown to be long-lived and
short-lived PCs, allowing for continuous protection against enteric pathogens (Landsverk et al.,
2017; Mesin et al., 2011). Despite these intrinsic mechanisms of defense, diarrheal diseases
remain one of the leading causes morbidity and mortality in children (Scallan, Hoekstra, et al.,
2011).
Aryl Hydrocarbon Receptor Plasma Cell Regulation
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor expressed
in cells throughout the hematopoietic system, and its activity impacts a variety of cell types in
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the immune system (Esser, 2012; Villa et al., 2017). Activation of the AhR occurs through
compounds generated during tryptophan metabolism, dietary compounds, and environmental
pollutants (Denison & Nagy, 2003; Villa et al., 2017). Aryl hydrocarbon receptor activation by
the prototypic ligand and environmental pollutant, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD),
has been shown to impact B cell gene expression levels, suppress antibody production, and
suppress terminal differentiation of B cells (Nagai et al., 2005; Tucker et al., 1986).
Previous studies in our laboratory have shown AhR activation with TCDD slowed the
recovery time of IgA-production in the serum, when compared to fecal IgA-production in
TCDD-treated mice immunized with cholera toxin (CT; King et al., 2018). Suppression of IgAproduction was predicted because of AhR-mediated suppression of B cell responses. However,
fecal IgA-production was similar between TCDD-treated, CT-immunized mice and CTimmunized mice only. These data suggest AhR activation differentially regulates systemic and
gut antibody responses. Given this information, we hypothesized that TCDD promotes gut
homing of IgA-producing B cells out of blood-associated lymphoid tissues and into gutassociated lymphoid tissues (GALT). Among the research done regarding the impact of AhR
activation on the immune system, the consequences on migration of all immune cells have yet to
be characterized. Though enhanced migration of regulatory T cells following AhR activation has
been demonstrated (Ehrlich et al., 2017; Ye et al., 2017), it is unknown if B cell migration is also
impacted.
Specific Aims and Research Hypotheses
A1

Determine the influence of AhR activation on the number of antigen-specific
antibody-secreting cells (ASC) in the spleens of CT-immunized mice.

H1

The number of nonspecific IgA-ASCs will be fewer in spleens of treated and
immunized mice compared to immunized mice only.
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H2

The number of CT-specific IgA-ASCs will be fewer in the spleens of treated
and immunized mice compared to immunized mice only.

A2

Determine the influence of in vitro AhR activation on murine B cell gut
migration markers.

H1

Cells treated in vitro with AhR agonists will have increased expression of
chemokine receptor 9 (CCR9), integrin a4b7, and integrin b7.

H2

Cells treated in vitro with AhR antagonists will have decreased expression of
CCR9, integrin a4b7, and integrin b7.

Figure 1
Proposed Migration Molecules Upregulated by Activation of the AhR.

Note. In this proposed model, clusters of differentiation (CD)19+ splenocytes stimulated to class
switch to IgA in the presence of AhR agonists will have increased expression of CCR9 and a4b7
integrin (denoted by, *). We hypothesize that activation of the AhR promotes gut-homing of
IgA-ASCs through upregulation of molecules associated with lymphocyte homing to the small
intestine. Activation of the AhR has been shown to increase CCR9 on CD4+ T cells (Ehrlich et
al., 2017), but it is unknown if AhR activation increases CCR9 on ASCs. Mucosal addressin cell
adhesion molecule-1, MAdCAM-1. Chemokine ligand 25, CCL25.
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Summary
Worldwide, childhood morbidity and mortality are largely attributed to by infectious
diarrheal disease (Scallan, Hoekstra, et al., 2011). Because the aryl hydrocarbon receptor is
activated by numerous nutritional and environmental factors, characterizing the influence of AhR
activation on intestinal antibody responses and B cell migration provides alternative therapeutic
opportunities for enhancing intestinal immune responses and barrier defense. The results of these
studies will contribute to the improvement of human health by filling a gap in knowledge
regarding dietary and environmental regulation of disease resistance.
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CHAPTER II
REVIEW OF LITERATURE
Innate Immunity
The innate immune system is the first layer of defense against pathogenic microbes and
toxins present in our environment (Riera Romo et al., 2016). Cellular and chemical constituents
of the innate immune system are responsible for the generation of inflammatory conditions in
response to pathogen invasion, thereby promoting pathogen elimination (Riera Romo et al.,
2016). Innate immunity additionally functions in the activation of the adaptive immune system
for assistance in pathogen elimination during later stages of infection (Akira et al., 2006). The
adaptive immune system relies on the innate immune system for activation in the case of a newly
encountered pathogen, but once activated, the adaptive immune system can provide long-term
protection against reinfection (Akira et al., 2006). This characteristic is unique to the adaptive
immune system, as the innate immune system does not provide long-term protection against a
pathogen that has been previously encountered (Akira et al., 2006).
Physical and Chemical Barriers
Epithelial cells of the skin provide physical barriers between the external environment
and the internal body system (Eyerich et al., 2018). The skin provides chemical protection
through secretory factors such as lysozyme or antimicrobial peptides thereby contributing to
preventing infection. Internal epithelial cells, those found lining respiratory, gastrointestinal, and
urogenital tracts provide defense through the secretion of mucins and other antimicrobial
peptides (Riera Romo et al., 2016). The viscosity of mucus decreases the capacity for pathogenic
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molecules or organisms to adhere to mucosal epithelium. Coupled with physical barriers,
chemical barriers such as the acidic pH of the gut and skin inhibit survival or growth of some
pathogenic microbes (Eyerich et al., 2018). Pathogens that breach physical and chemical barriers
trigger the activation of plasma proteins, referred to as complement, that elicit the recruitment of
various immune cell types for pathogen elimination.
Complement System
Complement proteins are soluble plasma proteins produced by the liver that assist in
pathogen elimination (Merle et al., 2015). These plasma proteins activate different pathways in
the presence of pathogens, referred to as the complement cascade and act in plasma, tissues, on
and within cells (Merle et al., 2015; Riera Romo et al., 2016). Through enhancing phagocytosis,
direct attack on pathogens, and inflammatory responses, the complement system provides the
second layer of innate defense (Riera Romo et al., 2016). Complement proteins enhance
opsonization, whereby a coated pathogen is readily destroyed by phagocytic cells (Merle et al.,
2015). Cleavage of complement proteins results in the formation of the membrane attack
complex, that acts to form a pore on the membrane of a pathogen resulting in lost membrane
integrity (Bubeck, 2014). Some small complement proteins resulting from protein cleavage
during the complement cascade act on endothelial cells to increase vascular permeability,
increase expression of cell adhesion molecules, and increase the production of chemical signals
to enhance migration of innate and adaptive immune cells to the site of pathogenic invasion or
infection (Bossi et al., 2011; Lozada et al., 1995).
Pathogen and Damage
Recognition
Innate immune cells and some subtypes of adaptive immune cells express patternrecognition receptors, expressed intracellularly and extracellularly, and interact with foreign
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intracellular microbes, extracellular microbes, or damaged cells (Akira et al., 2006; Riera Romo
et al., 2016). Pattern recognition receptors of different classes, such as toll-like receptors or
nucleotide-binding oligomerization domain-like receptors interact with microbes through
repeating molecular patterns, known as pathogen-associated molecular patterns (PAMPs) or
damaged cells in the form of damage-associated molecular patterns (DAMPs; Akira et al., 2006;
Riera Romo et al., 2016; Tang et al., 2012). A well-known PAMP, lipopolysaccharides (LPS) is
expressed by some bacteria, acts as a PAMP whereby interaction with host toll-like receptors
initiates an inflammatory response to eliminate the foreign microbe present within the internal
environment (Akira et al., 2006). Damage-associated molecular patterns are released in response
to invasion, cell death, and cellular stress, thereby signaling the presence of a foreign microbe
(Tang et al., 2012). Interaction between pattern recognition receptors and PAMPs/DAMPs
promotes the activation of signaling pathways to enhance pathogen elimination.
Cellular and Chemical
Constituents
Innate immune cells provide cell-mediated immunity through phagocytosis, secretion of
soluble factors with antimicrobial properties, and secretion of signaling factors (Riera Romo et
al., 2016). Innate phagocytic cells such as macrophages, granulocytes, and B-1 cells interact with
receptors on the surface of microbes through pattern recognition receptors to bind and internalize
them into an endocytic vesicle for lysosomal degradation. Mast cells are critical mediators of
allergic reactions and stimulate inflammatory responses in the presence of antibodies produced
by ASCs (Min et al., 2007). Innate lymphoid cells (ILCs) such as natural killer cells act as
cytotoxic effector cells against viruses and intracellular microbes to kill infected cells (Riera
Romo et al., 2016). B cells of the innate immune system are referred to as B-1 cells and provide
rapid responses against some pathogenic microbes. B-1 cells constitutively produce soluble

8
proteins that contribute to the neutralization and phagocytosis of pathogens, these proteins are
referred to as “natural antibodies” (Cerutti, 2008; Rothstein et al., 2013).
Chemical signals in the form of cytokines, are produced by immune cells and other
systemic cell types promote or dampen inflammatory responses (Riera Romo et al., 2016).
Various classes of cytokines are found in the form of interleukins (IL), interferons, tumor
necrosis factors and transforming growth factors (TGFs; Riera Romo et al., 2016; Sokol &
Luster, 2015). Cytokines from different classes have varying functions related to immune cell
proliferation and differentiation and pro- or anti-inflammatory responses, while contributing to
other systemic functions such as wound repair (Riera Romo et al., 2016). Chemokines are a
subset of cytokines that contribute to the development of lymphocytes and function as
chemoattractant molecules to direct innate and adaptive immune cells from circulation to sites of
infection (Sokol & Luster, 2015).
Antigen Presentation
The presentation of antigens by antigen-presenting cells (APCs) allows for activation of
some adaptive immune cells and amplification of inflammatory responses to promote pathogen
elimination. Antigens are presented on major histocompatibility complexes of class I or II (MHC
I and MHC II, respectively). Major histocompatibility complex class I is expressed on all
nucleated cells, while the expression of MHC II is restricted to professional APCs (Neefjes et al.,
2011). All nucleated cells act as APCs, while professional APCs include dendritic cells (DCs),
macrophages, and B cells. Antigen processing or uptake determines which class of MHC the
antigen will be presented on (Neefjes et al., 2011). Phagocytosis of extracellular pathogens
results in antigen fragments that are transferred to the cell surface for presentation on MHC II
molecules and intracellular pathogens are presented on MHC I molecules (Neefjes et al., 2011).
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Dendritic cells are the only known cell type that is capable of presenting antigen fragments from
extracellular pathogens on MHC I, through a process referred to as cross-presentation (Albert et
al., 1998; Kurts et al., 2010). Cross-presentation on MHC I allows for the activation of some
subsets of adaptive immune cells that would not otherwise be activated in response to some
intracellular pathogens, cross-presentation additionally contributes to preventing the formation of
tumors by activating cells with the capacity to killing host cells (Kurts et al., 2010).
Adaptive Immunity
The adaptive immune system consists of T and B lymphocytes generated in the thymus
and bone marrow, respectively (Bonilla & Oettgen, 2010). B cells of the adaptive immune
system are referred to as conventional (or B-2) B cells, opposed to B-1 cells that generate
‘natural’ antibodies within the innate immune system (Cerutti, 2008). After development within
the primary lymphoid organs, T and B cells migrate to secondary lymphoid organs which include
lymph nodes and the spleen (Bonilla & Oettgen, 2010). Within secondary lymphoid tissues, T
and B cells capture antigens from lymphatic fluid and blood (Bonilla & Oettgen, 2010). While
the specific location of adaptive immune responses is directed by chemokines allowing for T and
B cells to migrate to locations outside of secondary lymphoid organs (Bonilla & Oettgen, 2010).
Distinct from the innate immune system, the adaptive immune system has a wider repertoire of
antigen recognition through genetic rearrangement that occurs during development (Bonilla &
Oettgen, 2010). The adaptive immune system generates immunological memory, whereby
primary exposure to an antigen generates T and B cells that provide long-term protection against
reinfection (Bonilla & Oettgen, 2010). The generation of long-lived memory lymphocytes allows
for rapid reactivation upon infection with an antigen encountered months to years prior, eliciting
more rapid pathogen elimination (Bonilla & Oettgen, 2010).
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T Lymphocytes
T Lymphocyte Development
T lymphocytes arise from progenitors generated in the bone marrow; these progenitors
migrate to the thymus for the remainder of T cell development and maturation (Luckheeram et
al., 2012). T cell development begins with cells that do not express T cell markers, CD4 or CD8
and are referred to as double negative cells (Hosokawa & Rothenberg, 2021). Double negative
cells progress towards expressing CD4 and CD8 simultaneously, as double positive cells;
followed by differentiation towards single positive cells (Hosokawa & Rothenberg, 2021).
Double positive T cells express T cell receptors (TCRs) in the thymus that were genetically
rearranged during development for the recognition of specific antigens (Hosokawa &
Rothenberg, 2021). T cell receptors in combination with CD4 or CD8, recognize antigen
presented on MHC II or MHC I, respectively, for T cell selection in the thymus (Moran &
Hogquist, 2012; Neefjes et al., 2011). If a T cell expresses a TCR with no recognition of selfpeptides presented on MHC (Luckheeram et al., 2012; Moran & Hogquist, 2012). Although,
strong TCR affinity for the peptide-MHC drives the cell towards apoptosis (negative selection),
and low affinity TCR-MHC interactions enforcing survival, referred to as positive selection
(Moran & Hogquist, 2012). Following thymic development and selection, surviving T cells will
differentiate into CD4+ helper T cells or CD8+ cytotoxic T cells and migrate to peripheral
lymphoid tissues, that include the spleen, lymph nodes, and mucosal lymphoid tissues for antigen
recognition and activation (Hosokawa & Rothenberg, 2021; Luckheeram et al., 2012; Masopust
& Schenkel, 2013).
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Activation and Differentiation
T cells recognize antigens when presented on the surface of APCs (Luckheeram et al.,
2012). T cells must receive co-stimulation by co-stimulatory molecules to prevent anergy, or
lack of response prior to activation and differentiation (Bour-Jordan et al., 2011; Luckheeram et
al., 2012). Cytokine signaling from APCs direct T cell differentiation into various subsets of
effector T cells (Luckheeram et al., 2012; Zhu, 2018). T cells expressing CD8 differentiate into
cytotoxic T cells, that are important for defense against viruses and other intracellular pathogens
through MHC I molecules on infected cells. T cells expressing CD4 further differentiate into
several subclasses of T helper cells (Th1, Th2, Th17), regulatory T cells, or follicular T helper
cells (Tfh; Luckheeram et al., 2012).
Subclasses of T helper cells (Th1, Th2, Th17), assist in defense against varying pathogens
(Luckheeram et al., 2012; Zhu, 2018). T Helper 1 cells function in defense against intracellular
pathogens (i.e., viruses), Th2 cells protect against extracellular parasites (i.e., helminths), and
Th17 cells are protective against extracellular bacteria and fungi (Zhu, 2018). Each subtype of T
helper cell is characterized by the types of cytokines produced, for example, Th1 cells produce
interferon-g which activates macrophages and enhances phagocytosis for pathogen elimination
(Zhu, 2018). While Th2 cells produce IL-5, mediating the recruitment of eosinophils for defense
against helminths (Zhu, 2018). Regulatory T cells function as immune regulators to prevent
development of autoimmunity and suppress T cell responses (Zhu, 2018). Follicular T helper
cells interact with naïve B cells to promote B cell activation and class switch recombination
(CSR; Zhu, 2018). Following selection and maturation within the thymus, naïve T cells circulate
through secondary lymphoid tissues in search of antigens (Masopust & Schenkel, 2013).
Activated T cells may become effector T cells for pathogen elimination or memory T cells,
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providing protection against previously encountered antigens (Masopust & Schenkel, 2013).
Activated effector or memory T cells preferentially migrate to sites of infection or remain within
the peripheral lymphoid tissue to provide B cell help (Masopust & Schenkel, 2013).
B Lymphocytes
The adaptive immune system includes the humoral immune system, in which B cells are
a critical component. Notably, B cells of the adaptive immune system are referred to as B-2 cells.
B-2 cells are distinct from B-1 cells that originate from the fetal liver opposed to the bone
marrow, B-1 cells undergo little or no genetic rearrangement to strengthen antibody-antigen
interactions resulting in antibodies with lowered affinity for antigens when compared alongside
B-2 cell antibodies (Rothstein et al., 2013). Collectively, B cells act as professional APCs and
produce antigen-specific antibodies that contribute to the neutralization and removal of
pathogens.
Subsets of naïve B-2 cells include follicular B cells and marginal zone B cells (Nutt et al.,
2011). As named, follicular B cells reside within follicles of secondary lymphoid tissues (lymph
nodes and the spleen) and make up most of naïve B cells, while marginal zone B cells are found
within the marginal zone of the spleen (Nutt et al., 2011). Follicular B cells can differentiate into
plasma cells or memory B cells, following antigen encounter and help from CD4+ T cells (Nutt
et al., 2011). Memory B cells provide immunological memory, allowing for long-lasting
protection against a pathogen that was previously encountered by eliciting a more rapid response
time upon reinfection.
B Lymphocyte Receptors
B cell receptors (BCRs) function as membrane-bound immunoglobulins or antibodies
(Matthews et al., 2014). The structure of a BCR is identical to that of the secreted antibody,
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except for portions of the constant region (Figure 2). They are both composed of two heavy and
two light chains, held by disulfide bonds. Heavy and light chains contain variable (V) and
constant regions. Binding of antigens by the antibody occurs within the V region (Matthews et
al., 2014; Schroeder & Cavacini, 2010). The V region is genetically modified during B cell
development in the bone marrow to promote variability, allowing for specific recognition of a
wider array of antigens. Constant regions are more evolutionarily conserved compared to
variable regions but exist in different forms that are termed isotypes.
Figure 2
B Cell Receptor and Antibody Structure.

Note. Illustrates the B cell receptor (BCR), identical to that of the secreted antibody. The BCR is
composed of two light (L) and two heavy (H) chains, bound by disulfide bridges. Variable (V)
regions are locations for antigen binding, while constant (C) regions allow for opsonization of
antigens.
Different isotype classes promote the elimination of antigens at distinct locations within
the body (Stavnezer & Schrader, 2014). Secreted antibodies function to neutralize pathogens,
enhance phagocytosis through opsonization and activate complement pathways (Inamine et al.,
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2005). The capacity for antibodies to enhance the elimination of pathogens by neutralization,
phagocytosis, or opsonization varies dependent upon the isotype as some isotypes may enhance
one or more of these processes at a greater rate than others.
B Lymphocyte Development
B cells arise from progenitor cells in the bone marrow; in the bone marrow, B cells
undergo gene recombination for genes encoding for BCRs during a process known as V(D)J
recombination. Variable, diversity (D) and joining (J) gene segments encode heavy chains for
BCRs and antibodies (Cerutti, 2008). Within the bone marrow, double stranded breaks of the
DNA require end-joining to repair, allowing for variations between each segment that result in a
large and varied repertoire of BCRs (Matthews et al., 2014). Following V(D)J recombination, the
cell is referred to as a precursor B cell. Within secondary lymphoid tissues, precursor B cells
undergo somatic hypermutation for the light chain, involving the combination of V and J
segments within the light chain loci (Nemazee, 2017). Following somatic hypermutation,
immature B cells now express BCRs with altered affinity in the form of immunoglobulin M, as
defined by the constant region (Nemazee, 2017). Immunoglobulin M+ immature B cells remain
within secondary lymphoid tissues for antigen encounter.
Activation and Differentiation
Following migration from the bone marrow, immature IgM+ B cells co-express IgD and
is now referred to as an IgM+IgD+ mature naïve B cell (Xu et al., 2012). Within follicles of
secondary lymphoid tissues, mature B cells may bind soluble antigen or antigen presented on
APCs. If the antigen is recognized by BCR binding the B cell will migrate towards Tfh cells
through the upregulation of chemokine receptor 7, for antigen presentation on MHC class II
(Stebegg et al., 2018). If the antigen is recognized by the Tfh cell, the B cell will receive co-
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stimulation through CD40 ligand expressed on B cells and CD40 on T cells, preventing anergy
(Chen et al., 2009; Ise & Kurosaki, 2019; Stebegg et al., 2018). Recognition by the Tfh cell
triggers the release of B cell activating cytokines to stimulate clonal expansion, such as
proliferation-inducing ligand and B cell activating factor (Chen & Cerutti, 2010; Ise & Kurosaki,
2019; Merkenschlager et al., 2021). Once activated, the B cell may progress to the germinal
center, a specialized structure within secondary lymphoid tissues that forms because of infection
or immunization, consisting of light and dark zones. Within the dark zone, the mature B cell will
undergo clonal expansion (Merkenschlager et al., 2021). Alternatively, the activated B cell may
divide outside of the germinal center and differentiate into short-lived PCs or memory B cells or
re-enter the light zone for further somatic hypermutation (Ise & Kurosaki, 2019; Stebegg et al.,
2018). During clonal expansion activation-induced cytidine deaminase (AID) introduces
mutations into the V coding region of the DNA (Inamine et al., 2005; Kräutler et al., 2017;
Matthews et al., 2014; Qiao et al., 2017; Schroeder & Cavacini, 2010; Stavnezer & Schrader,
2014; Xu et al., 2012). These mutations lead to increased or decreased antibody affinity for the
activating antigen. These plasmablasts progress to the light zone of the germinal center for
positive selection based on antibody affinity (Schroeder & Cavacini, 2010). Interaction with Tfh
cells or follicular DCs will allow for class switch recombination (Kräutler et al., 2017), which
refers to changing the antibody isotype, such as switching from IgM to IgE. Following CSR,
centrocytes will differentiate further into long-lived plasma cells or memory B cells (Kräutler et
al., 2017; Matthews et al., 2014; Phan et al., 2006).
B cells require additional signals following antigen recognition to prevent anergy from
other cell types or antigens that provide required signals independent of T cell help and are
referred to as thymus-independent (TI) antigens. Thymus-independent antigens like LPS with
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repetitive molecular patterns provide sufficient stimulation and B cell activation through toll-like
receptors, triggering differentiation into short-lived plasma cells producing low-affinity memory
B cells (Inamine et al., 2005; Montes et al., 2007; Schroeder & Cavacini, 2010).
Lipopolysaccharides are referred to as a polyclonal B cell activators and induce B cell
proliferation and ASC generation in the absence of T cell help, notably the antibodies secreted by
the clones are not antigen-specific (Montes et al., 2007). Protein antigens are thymus-dependent
(TD) antigens that provide sufficient signaling for B cell activation but require T cell help.
Regulation of Development and
Differentiation
B cell development and differentiation are regulated by a variety of transcription factors
that provide mutual antagonism, as shown in figure 3 (Lin et al., 2002; Minnich et al., 2016; Nutt
et al., 2011; Ochiai et al., 2013; Sciammas et al., 2006, 2011; Shaffer et al., 2002, 2004; Tellier et
al., 2016). Transcriptional regulators contributing to B cell fate and germinal center B cell
development include paired box 5 (Pax5), B cell lymphoma 6 (Bcl6), and BTB and CNC
homology 2 (Bach2); some contribute to plasma cell differentiation directly or indirectly (Nutt et
al., 2011; Sciammas et al., 2011). Transcriptional regulation of promoting ASC development
occurs through interferon regulatory factor 4 (IRF4), B lymphocyte-induced maturation protein 1
(Blimp1), and X-box binding protein 1 (Xbp1; Minnich et al., 2016; Ochiai et al., 2013; Tellier
et al., 2016).
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Figure 3
Signaling Model Representing the Proteins Involved in Plasma Cell Differentiation.

Note. Illustrates the feedback loops involved in timing plasma cell differentiation and
immunoglobulin gene expression. Positive regulation is depicted by → , negative regulation by
⊣. Adapted from North et al. (2009). Unfolded protein response, UPR.
B cell lineage commitment in the bone marrow requires Pax5 (Nutt et al., 2011). The
expression of Pax5 induces expression of Bach2 and Bcl6, both function in repressing plasma
cell differentiation (Nutt et al., 2011; Sciammas et al., 2011). Paired box 5 contributes to class
switch recombination and somatic hypermutation through promoting Aicda expression and
maintaining the identity of mature B cells by activating genes encoding for B cell surface
receptors and transcriptional regulators (Minnich et al., 2016; Sciammas et al., 2006, 2011;
Shaffer et al., 2002). Paired box 5 represses J chain, Igµ, and Ig heavy chain transcription, and
stimulating Bcl6/Bach2, ultimately suppressing plasma cell differentiation (Nutt et al., 2011;
Shaffer et al., 2002). B cell lymphoma 6 is essential for the formation of germinal center B cells
and contributes to B cell development in the bone marrow (Nutt et al., 2011). B cell lymphoma 6
represses Blimp1, ultimately repressing plasma cell differentiation (Nutt et al., 2011). The
expression of Pax5 positively regulates the expression of Bach2 and contributes to timing ASC
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formation (Nutt et al., 2011). Extrafollicular and germinal center B cell development require the
expression of Bach2 (Nutt et al., 2011; Sciammas et al., 2011).
Plasma cell differentiation involves transcription factors: IRF4, Blimp1, and Xbp1
(Minnich et al., 2016; Ochiai et al., 2013; Tellier et al., 2016). Interferon regulatory factor 4 is
induced by mitogenic stimulation or BCR crosslinking (Sciammas et al., 2006, 2011) and
activates the PR domain zinc finger protein 1 (Prdm1) gene. The Prdm1 gene is responsible for
encoding Blimp1 contributes to the induction of plasma cell differentiation (Minnich et al., 2016;
Nutt et al., 2011; Sciammas et al., 2011). Notably, levels of IRF4 influence ASC fate, low levels
of IRF4 promote CSR while high levels repress Bcl6 and consequently activate Blimp1 (Nutt et
al., 2011). B lymphocyte induced maturation protein 1 is only expressed by ASCs and functions
as a direct transcriptional repressor for some transcription factors such as, c-Myc, Bcl6, Aicda,
and Pax5 to enforce plasma cell fate (Ise & Kurosaki, 2019; Lin et al., 2002; Minnich et al.,
2016; Nutt et al., 2011; Sciammas et al., 2006; Shaffer et al., 2002; Tellier et al., 2016).
Additionally, Blimp1 functions in expanding the endoplasmic reticulum (ER) and increasing
protein synthesis for antibody-secreting cells, or PCs while regulating negatively regulating
expression of Bcl6 and Pax5 (Ochiai et al., 2013; Sciammas et al., 2006, 2011; Shaffer et al.,
2002). Plasma cells account for secreting large amounts of antibodies through the unfolded
protein response, which is a mechanism for sensing the passage of antibodies activated because
of ER stress (Ise & Kurosaki, 2019; Minnich et al., 2016; Nutt et al., 2011; Tellier et al., 2016).
The unfolded protein response pathway maintains the secretory capacity of plasma cells and is
enforced by Blimp1 through the downregulation of Pax5 (Lin et al., 2002; Nutt et al., 2011;
Tellier et al., 2016). Repression of Pax5 results in allowing for further activation of Xbp1,
allowing for activation transcription of genes responsible for proteins within the ER (Sciammas
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et al., 2006; Shaffer et al., 2002, 2004). The antagonistic characteristics of the transcription
factors involved in B cell development and differentiation allow for careful and regulated timing
of each stage from development in the bone marrow to ASC fate.
Class Switch Recombination
Class switch recombination is a process of irreversible DNA recombination by which
AID deaminates cystine residues in switch regions within the constant region locus resulting in
different antibody isotype expression from IgM+IgD+ to IgE, IgG, or IgA (Matthews et al., 2014;
Qiao et al., 2017; Stavnezer & Schrader, 2014; Xu et al., 2012). Expression of AID is observed
in mature B cells during somatic hypermutation and CSR and requires stimulating conditions to
be transcribed from the Aicda locus (Muramatsu et al., 1999; Xu et al., 2012). Stimulating
signals that initiate transcription of AID can arise from TI or TD antigens. B cell activation from
TI-antigens stimulates CSR through BCR cross linking and interactions with pattern recognition
receptors expressed on B cells (Xu et al., 2012). Under TD conditions, B cell CD40 interacts
with CD40 ligand expressed on Tfh cells, which provide the required stimulation to initiate CSR.
In the absence of CD40-CD40 ligand interactions, B cells express and secrete only IgM, due to
AID being a requirement for CSR. The absence of AID results in hyper IgM syndrome and
humoral immunodeficiency, this is also observed in individuals with AID mutations (Xu et al.,
2012). The selection of isotype change during CSR is directed by cytokines produced by Tfh or
follicular DCs that provide secondary stimulation and can promote class switch to one isotype
while simultaneously inhibiting class switch to another isotype. Secondary stimulation arises
from cytokines including IL-4 and TGF-b, IL-4 promotes CSR to IgE and some subclasses of
IgG, while TGF-b promotes IgA-CSR (Xu et al., 2012).
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Immunoglobulin Classes
Antibody isotypes of five classes and various subclasses are found in different
compartments of the body in varying concentrations with specific functions. All antibodies (IgM,
IgD, IgG, IgE, and IgA) are characterized by the heavy chain constant domains (Schroeder &
Cavacini, 2010; Xu et al., 2012). Antibodies aid in pathogenic elimination through enhancing
opsonization and activating complement pathways; isotype classes can have varying capacities to
act as an opsonin and activate complement.
Immunoglobulin M is expressed first during B cell development and does not require
CSR. Secretory IgM it is typically found in pentameric structures comprised of multiple
monomers joined by a joining, or J-chain (Schroeder & Cavacini, 2010). The pentameric
structure of IgM allows for high avidity, or antigen binding strength, making secretory IgM
efficient in enhancing opsonization (Schroeder & Cavacini, 2010; Xu et al., 2012).
Immunoglobulin D is often co-expressed with IgM and is used as a marker of B cell
development, while IgM is expressed early in B cell development; the expression of IgD takes
place following B cell migration into secondary lymphoid tissues (spleen and lymph nodes).
Following antigen-activation, the transcription and expression of IgD is repressed (Chen &
Cerutti, 2010; Noviski et al., 2018). Although, it is unknown as to why co-expression of IgM and
IgD is observed, as loss of one isotype is compensated for by increasing expression of the other
and both have identical antigen specificity (Chen & Cerutti, 2010; Chen et al., 2009; Noviski et
al., 2018). The function of secretory IgD remains enigmatic because it has not been shown to
participate in specific effector mechanisms, in addition to being found in low levels in serum
with a short half-life when compared to secretory IgG.
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Immunoglobulin G exists in four subclasses (IgG1, IgG2, IgG3, IgG4) with varying
capacity to enhance opsonization, complement activation, but with the capacity for placental
transport. Collectively, IgG represents most antibodies in the body and has the longest half-life
compared alongside other antibody isotypes (Schroeder & Cavacini, 2010). However, IgG4 is
the only subclass of IgG that does not participate in complement activation but assists more in
the neutralization of polysaccharide antigens in combination with IgG2 (Schroeder & Cavacini,
2010). Correspondingly, IgG antibodies produced against protein antigens are typically IgG1 and
IgG3 (Schroeder & Cavacini, 2010).
Large extracellular antigens such as helminths are associated with IgE, in addition to
contributing to hypersensitivity reactions (Schroeder & Cavacini, 2010). However, IgE does not
contribute to complement activation and has the shortest half-life of all isotypes, it participates
strongly in the recruitment and activation of mast cells and other granulocytes (Galli & Tsai,
2012; Schroeder & Cavacini, 2010).
Mucosal surfaces are protected by IgA, although it provides weak complement activation,
it is critical for protection against infection along mucosal tissues (Schroeder & Cavacini, 2010).
Monomeric IgA is typically found in serum, with multimeric IgA predominating mucosal
surfaces allowing for transport across epithelial cells and neutralization of antigens.
Immunoglobulin A is transported via J-chain interactions with polymeric Ig receptors expressed
on mucosal epithelial cells allowing for antigen retrieval and sampling (Cerutti, 2008; Mantis &
Forbes, 2010; Schroeder & Cavacini, 2010).
Tolerance
Central tolerance refers to the elimination of self-reactive B and T cells in the bone
marrow and thymus, respectively. Although there is potential for self-reactive cells to pass
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through central tolerance mechanisms, peripheral tolerance provides an additional layer of
regulation prior to the generation of effector cells (Kucuksezer et al., 2020; Nemazee, 2017).
Peripheral tolerance for IgM+IgD+ B cells occurs in peripheral lymphoid tissues whereby B cells
with lowered or absent antigen binding affinity after somatic hypermutation are eliminated by
apoptosis (Inamine et al., 2005; Nemazee, 2017). Peripheral tolerance for T and B cells is
mediated through co-stimulatory signals, that allow for activation and differentiation; in the
absence of these signals, lymphocytes become anergic to prevent the development of
autoimmune reactions (Bour-Jordan et al., 2011). Subsets of CD4+ T cells, regulatory T cells,
contribute to tolerance through the production of anti-inflammatory cytokines to suppress
inappropriate immune responses (Bour-Jordan et al., 2011).
Mucosal Immunity
The mucosal immune system is comprised of the gastrointestinal tract, nasopharynx,
urogenital tract, oral cavity, lungs, and eyes. Mucosa-associated lymphoid tissues contain a
variety of innate and adaptive immune cell types. Gut-associated lymphoid tissues represent
most of mucosa-associated lymphoid tissues and is the largest peripheral lymphoid tissue in the
body (Ohno, 2016). Antigens within GALT are sampled directly from mucosal surfaces for
immune cell activation. Sampling antigens directly from mucosal surfaces is distinct from other
peripheral induction sites (lymph nodes and the spleen) due to the lack of afferent lymphatics
within GALT (Ohno, 2016). Notably, GALT contains the largest number of IgA-ASCs and T
cells in the body (Mora et al., 2006).
Structure of the Intestinal
Epithelium
The small and large intestine differ in structure and cellular composition to allow for
areas with higher absorption rates, specifically within the small intestine. The small intestine
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contains epithelial protrusions, that are referred to as villi, and are not found within the large
intestine or colon. Villi protruding into the lumen increase mucosal surface area and nutrient
absorption, thereby limiting damage by stool transitioning towards the colon (Allaire et al.,
2018). Within the base of villi there are invaginations, known as the crypts of Lieberkühn, which
contain multipotent stem cells that allow for self-renewing epithelium (Allaire et al., 2018;
Umar, 2010). Intestinal cells are renewed continuously, and old cells are sloughed from the tips
of villi to maintain barrier integrity and absorptive capacity (Umar, 2010).
Cellular and Chemical
Constituents
Stem cells within intestinal crypts give rise to a variety of intestinal epithelial cells
(IECs): enteroendocrine cells, enterocytes, tuft cells, goblet cells, Paneth cells, and microfold
cells (Crosnier et al., 2006). The stem cells within GALT allow for self-renewal and repair, both
are critical for maintaining barrier function and absorptive functions (Crosnier et al., 2006;
Umar, 2010). Intestinal homeostasis is maintained by all cell types; enteroendocrine cells secrete
gastrointestinal hormones and enterocytes allow for nutrient absorption (Umar, 2010). Tuft cells
are chemosensory cells and contribute to protection against helminth infections (Allaire et al.,
2018). Goblet cells produce mucus and antimicrobial peptides and assist in antigen transfer to
DCs and macrophages (Mantis & Forbes, 2010). Paneth cells reside within intestinal crypts and
provide protection to neighboring stem cells through the production of antimicrobial peptides in
response to DAMPs and PAMPs (Mantis et al., 2011; Ohno, 2016). Microfold cells contain
‘microfold cell pockets’ and are located within follicle-associated epithelium that underlie
Peyer’s patches (PPs) and function as sites of luminal antigen uptake and induction sites for
immune activation (Allaire et al., 2018; Mantis & Forbes, 2010; Ohno, 2016). Although some
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cell types found in the small intestine are also found within the colon, Paneth cells and microfold
cells are unique to the small intestine (Allaire et al., 2018).
Epithelial cells express MHC I throughout the body, IECs preferentially express both
MHC I and II for presentation to CD4+ T cells. Intestinal epithelial cells recognize DAMPs and
PAMPs through toll-like receptors and mediate immune responses through the production of
cytokines and chemokines and determine T cell differentiation and B cell CSR indirectly through
DCs (Allaire et al., 2018). Dendritic cells may capture antigens by sending projections through
gut epithelial layers via expression of tight junction proteins, or through assistance from goblet
cells. Goblet cells assist in antigen uptake through the formation of goblet cell-associated antigen
passages, additionally DCs gain access to antigens within microfold cell pockets that serve as
sites of luminal antigen uptake (Allaire et al., 2018; Ohno, 2016).
Intraepithelial lymphocytes (IELs) are found between epithelial cells and may or may not
express TCRs, TCR-IELs are ILCs with TCR+IELs populations containing T cells (OlivaresVillagómez & Van Kaer, 2018). Intraepithelial lymphocytes that are TCR+ are referred to as
intraepithelial T cells and are comprised of two subsets, referred to as induced and natural
(Olivares-Villagómez & Van Kaer, 2018). Induced IELs are T cells that homed to the intestine
following antigen encounter and activation, while natural IELs are T cells that have homed to the
intestine immediately following thymic development (Olivares-Villagómez & Van Kaer, 2018).
Intraepithelial T cells contribute to barrier integrity through the production of growth factors and
positive regulation of tight junction formation between intestinal epithelial cells (Nielsen et al.,
2017). Effector intraepithelial T cells within GALT are primarily CD4+ and are directed towards
Th2 and Th17 differentiation. T Helper 17 cells produce IL-17 and IL-22, which contribute to
barrier integrity through promoting the formation of tight junctions between epithelial cells,
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antimicrobial peptide production and mucus production. Intraepithelial lymphocytes that do not
express a TCR within GALT consist of ILCs of different subsets (ILC1, ILC2, ILC3), that
perform functions like those of differentiated Th cells (Olivares-Villagómez & Van Kaer, 2018).
Innate lymphoid cells contribute to protection and epithelial homeostasis through the production
of IL-17 and IL-22, but also contribute to tissue damage through natural killer cell (ILC1s)
activity (Cervantes-Barragan & Colonna, 2018; Qiu et al., 2012; Sokol & Luster, 2015).
Additionally, ILCs act as APCs through MHC II molecule expression while mediating
macrophages and DCs through cytokine production.
Mucosal B Cells
The gut contains the largest number of IgA-ASCs in the body, moreover secretory IgA
(SIgA) is the predominant antibody found in the gut and is critical for defense along intestinal
epithelium (Gloudemans et al., 2013; Lycke et al., 1999; Mantis et al., 2011). However, many of
the IgA-ASCs found within the lamina propria were activated within GALT, while systemically
activated B cells do not result in as many IgA-ASCs (Mora, 2008). Peyer’s patches serve as
induction sites for IgA-CSR and J-chain expression within GALT and rely on mucosal DCs
present within PPs that produce cytokines such as, proliferation-inducing ligand, B cell
activating factor, and TGF-b allowing for IgA synthesis in a TI-dependent manner (Cerutti,
2008; Gloudemans et al., 2013; Mantis & Forbes, 2010; Mantis et al., 2011). Immunoglobulin A
synthesis is also regulated by TD-dependent pathways through CD40 ligand co-stimulation from
activated CD4+ T cells and the expression of TGF-b (Gloudemans et al., 2013). Class switch
recombination within the gut directed by TI or TD antigens is largely directed towards favoring
IgA synthesis, opposed to directing CSR to an alternative isotype (IgG or IgE; (Cerutti, 2008).
Class switch recombination to IgA occurs in a matter of days following infection with a TI
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antigen, such as LPS. Although LPS and TGF-b allow for IgA-CSR; in vitro, high levels of IgAsecretion require BCR crosslinking, that can be achieved with dextran-conjugated IgD antibodies
(Cerutti, 2008). B-1 cells constitutively produce IgA, allowing for compensation due to the
delayed response time required for IgA-CSR to occur in response to TI antigens (Cerutti, 2008).
Although, the IgA produced by B-1 cells has not undergone somatic hypermutation, resulting in
lower affinity when compared to the IgA produced by B-2 cells (Cerutti, 2008).
Secretory IgA binds and prevents antigens from infecting IECs by limiting antigen-IEC
interactions through trapping bacteria within the mucus layer (Mantis et al., 2011). The J-chain is
associated with effective mucosal protection, as it binds the polymeric Ig receptor expressed on
the basal surface of intestinal epithelial cells allowing for transcytosis and binding of luminal
antigens (Lycke et al., 1999; Mantis & Forbes, 2010). The polymeric Ig receptor transports
polymeric IgM, but to a much lesser extent as greater than 80% of intestinal secretory antibodies
are dimeric IgA (Lycke et al., 1999; Ohno, 2016). Immunoglobulin A-ASCs expressing J-chains
are recognized as critical for protection against intestinal pathogens (Lycke et al., 1999).
Secretory IgA is required for protection against the enteric toxin, CT, that is responsible
for the diarrheal disease associated with Vibrio cholerae. Cholera toxin is a well-studied and
potent mucosal immunogen (Elson & Dertzbaugh, 2005). Cholera toxin is a protein antigen
comprised of A and B subunits and does not induce oral tolerance but does allow for memory
responses in mucosal tissues (Elson & Ealding, 1984; Lycke & Holmgren, 1986). The B subunit
of CT binds a GM1 ganglioside receptor that is expressed on all nucleated cells (Elson &
Dertzbaugh, 2005). Following CT-B subunit-mediated endocytosis, the CT-A subunit increases
cyclic AMP within intestinal crypt cells, resulting in extensive chloride secretion and secretory
diarrhea (Elson & Dertzbaugh, 2005; Lycke, 1993). Secretory IgA provides critical protection
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against cholera toxin infection through binding GM1 ganglioside receptors, thereby blocking CTB subunit-mediated endocytosis of CT by epithelial cells (Lycke et al., 1999; Mantis & Forbes,
2010). Alternatively, SIgA contributes to protection by prohibiting antigenic entry through crosslinking or agglutination, whereby antigens are bound by CT-specific SIgA generated from
previous immunization against cholera toxin (Apter et al., 1993; Mantis & Forbes, 2010).
Gut-Homing
Following B cell activation within GALT, IgA-ASCs enter circulation and migrate to the
intestinal LP to provide protection against enteric pathogens through the production of SIgA.
Cellular migration, referred to as chemotaxis (Figure 4), is guided by the expression of cell
adhesion molecules on migrating cells and endothelial cells in addition to chemokines produced
by systemic and immune cell types (Habtezion et al., 2016; Mora et al., 2006). The expression of
some adhesion molecules or chemokine receptors are maintained on cells once they have
migrated to locations within GALT, others may no longer be expressed, suggesting that some
adhesion molecules are more important for migration compared to retention.
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Figure 4
Chemotaxis.

Note. Cell migration to sites of infection or tissue damage is a multistep process initiated by proinflammatory factors released by systemic and immune cells in the affected area. Some proinflammatory factors are associated with increasing expression of receptors on endothelial
surfaces for recognition by circulating immune cells. 1) Cells rolling along endothelial cells, 2)
Tethering to endothelial cells via molecular interactions, 3) Binding, 4) Extravasation and
migration directed by chemokine signaling.
Intestinal migration of immune cells requires the expression of integrin a4b7 (or a4b7
integrin) and CCR9, while localization within the intestinal compartments is directed by
expression of CCR9 or chemokine receptor 10 (CCR10). The expression of these migration
markers is critically linked to GALT-resident DCs. Metabolism of vitamin A by GALT DCs
produces retinoic acid (RA), allowing for upregulated expression of gut-homing markers on T
and B cells (Habtezion et al., 2016; Kang et al., 2011; Mora et al., 2006). B cells exposed to RA
in vitro upregulate a4b7 integrin and CCR9 (Mora et al., 2006). However, when RA was
removed, B cells downregulated expression of CCR9 (Mora et al., 2006). Supported by in vivo
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findings of downregulated CCR9 expression once the cells have migrated, suggesting that CCR9
is not required for retention, although critical for migration to GALT (Pabst et al., 2004).
Integrin a4b7, is a member of the integrin (Itg) family and Ig superfamily, and is a
heterodimer comprised of a4 and b7 integrin chains. Integrin a4b7 is expressed on most
peripheral lymphocytes (Kang et al., 2011; Lim et al., 1998). The a4b7 integrin heterodimer is
critical for PP adhesion in vitro, opposed to the heterodimer with b1 integrin, that allows for
migration to other mucosal and non-mucosal sites (Hamann et al., 1994; Kang et al., 2011;
Kunkel & Butcher, 2003). Integrin a4b7 binds the mucosal addressin cell adhesion molecule-1
(MAdCAM-1) that is expressed on PP high endothelial venules and LP endothelial cells
(Hamann et al., 1994; Lim et al., 1998). Integrin a4b7 also binds vascular-cell adhesion
molecule-1, expressed on inflamed endothelial cells and fibronectin, but at lower binding affinity
(Kang et al., 2011; Lim et al., 1998).
Chemokine receptors 9 and 10 allow for specific localization within GALT. Chemokine
receptor 9 interacts with chemokine ligand 25 (CCL25) constitutively expressed by IECs of the
small intestine (Pabst et al., 2004). Chemokine receptor 9 is expressed by most intestinal T cells
and IgA-ASCs that originate from both systemic and GALT induction sites (Mora et al., 2006;
Pabst et al., 2004). Although the expression of a4b7 integrin is characteristic of gut-homing
lymphocytes, and CCR9 participates largely in specific localization; expression of CCR9 is
similarly critical for intestinal immunity. Mice lacking CCR9 have been shown to have
significantly lower numbers of IgA+ plasma cells in small intestinal LP when compared to wildtype, paralleled with decreased migration to the small intestine observed in adoptive transfer
experiments; collectively resulting in reduced IgA responses following oral antigen challenges
thereby impairing intestinal immune responses (Pabst et al., 2004).
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Chemokine receptor 10 interacts with chemokine ligand 28 expressed by epithelial the
large intestine, colon, and mucosal tissues outside of GALT (Kunkel & Butcher, 2003).
Additionally, CCR10 is expressed on the majority of IgA+ PCs and has been proposed to be
linked to the terminal differentiation of B cells (Hu et al., 2011; Kunkel & Butcher, 2003).
Distinct from CCR9, CCR10 does not appear to be required for appropriate intestinal IgA
responses, which has been proposed to result from increased generation of IgA+ plasma cells
within isolated lymphoid follicles thereby allowing for compensation of IgA production in the
absence of CCR10 (Hu et al., 2011). However, IgA+ cells from CCR10-deficient mice have been
shown to contain fewer Ig heavy chain mutations when compared alongside wild-type mice,
suggesting that in the absence of CCR10, intestinal immune responses result in the generation of
lowered affinity IgA (Hu et al., 2011).
Immune Modulation
Immunization
Immunization is commonly known as vaccination, and frequently occurs during
childhood against well-known pathogens such as the varicella-zoster virus that causes chicken
pox or the annual flu vaccine, protective against influenza viruses. Vaccines are designed to
decrease mortality and morbidity within an effected population by mimicking pathogens such
that an immune response is stimulated without the associated disease (Zepp, 2010). Different
types of vaccines have been employed with varying capabilities in providing protection against
the pathogen. All vaccine types have the advantage of immune stimulation and consequent
immunological memory of the pathogen, albeit at different levels. Primary adaptive immune
responses require initiation by the innate immune system, but the innate immune cells lack
immunological memory (Clem, 2011). Long-term protection against a pathogen requires the
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generation of persistent antibodies and memory cells. Memory T and B cells maintain the
capacity for reactivation to against a pathogen months-to-years after initial exposure, allowing
for more rapid response times and elimination of pathogens (Ise & Kurosaki, 2019; Vetter et al.,
2018).
Nutritional
A variety of dietary compounds are required for survival, but additionally contribute to
regulating immune health and immune responses. Vitamins and their metabolic byproducts are
required for numerous physiological processes and developmental stages. Biologically active
forms of vitamins A and D contribute to immune cell regulation (Mora et al., 2008).
Systemically, the active form of vitamin D3 is typically associated with calcium and mineral
homeostasis (Bouillon et al., 1995). Innate immune cells, like macrophages and DCs have been
shown to be inhibited by the active form of vitamin D3 (Boonstra et al., 2001; Penna & Adorini,
2000). Additionally, vitamin D3 contributes to adaptive immunity and has been reported to
influence CD4+ T cell development and differentiation in vitro (Boonstra et al., 2001; Palmer et
al., 2011). Metabolism of vitamin A by GALT-resident DCs results in the production of retinoic
acid, which can enhance T cell proliferation with a reported opposite effect on B cells (Blomhoff
et al., 1992; Ertesvåg et al., 2009; Iwata et al., 2004). Dendritic cells within GALT contribute to
regulating B cell activation and CSR, like Tfh cells within peripheral lymphoid tissues (Mora,
2008). Dendritic cells resident within GALT enhance CSR to IgA under the influence of RA in
the presence of LPS (Mora et al., 2006; Tokuyama & Tokuyama, 1999).
Amino acids, like tryptophan, contribute to neuromodulation, protein synthesis, and
immune responses (Le Floc'h et al., 2011). Enzymatic breakdown of tryptophan is observed in
some antigen presenting cells during immune responses (Le Floc'h et al., 2011; McGaha et al.,
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2012). Catabolites of tryptophan contribute to the differentiation of CD4+ T cells into regulatory
T cells through activation of the AhR, a transcription factor that acts as an environmental sensor
(Fallarino et al., 2006; Mezrich et al., 2010).
Metabolic byproducts of vegetables contribute to immune cell gene regulation and
cytokine production (Yahfoufi et al., 2018). Polyphenols, classified as flavonoids are found in
fruits and vegetables and stimulate various cell signaling pathways (Recio et al., 2012). Some
flavonoids directly influence the differentiation of some innate and adaptive immune cells in
peripheral and mucosal lymphoid tissues (Karasawa et al., 2011). Notably, some flavonoids
contribute to anti-inflammatory processes through the inhibition of pro-inflammatory cytokine
production (Min et al., 2007). Regulatory T cells have been shown to be induced by some
flavonoids through AhR activation, like amino acid metabolites (Wang et al., 2012).
Collectively, polyphenols have been proposed to beneficially regulate inflammatory diseases and
mucosal immune responses (Ding et al., 2018; Recio et al., 2012; Wang et al., 2012; Yahfoufi et
al., 2018).
Aryl Hydrocarbon Receptor
Activation and Biological Function
The AhR is a cytosolic ligand-activated transcription factor of the Per-Arnt-Sim family of
proteins and is found in complex with heat shock protein 90, as shown in figure 5 (Ehrlich et al.,
2018; Mandal, 2005; Stejskalova et al., 2011; Zhou, 2016). Ligand binding allows for nuclear
translocation of the AhR complex through binding of the AhR nuclear translocator (ARNT). The
AhR and ARNT dimerize, releasing heat shock protein 90 and bind xenobiotic responsive
elements (Ehrlich et al., 2018; Mandal, 2005). The AhR-ARNT complex binding xenobiotic
responsive elements induces the transcription of xenobiotic metabolizing enzymes including,
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cytochrome P-450 1A1 and 1A2 (CYP1A1 and CYP1A2, respectively), in addition to inducing
the transcription of inhibitors for AhR activity, the AhR repressor (AhRR; Ehrlich et al., 2018;
Mandal, 2005; Mimura et al., 1999; Zhou, 2016). The AhRR functions directly in suppressing
AhR activity through blocking formation of the AhR-ARNT complex and competing for binding
of xenobiotic responsive elements (Mimura et al., 1999).
Figure 5
Canonical Pathway for Aryl Hydrocarbon Receptor Activation and Nuclear Translocation.

Note. The AhR resides within the cytoplasm in complex with heat shock protein 90 (hsp90), aryl
hydrocarbon receptor-interacting protein (AIP), and co-chaperone protein 23 (P23). Once
activated, the AhR complex translocates to the nucleus where the complex dissociates and the
AhR dimerizes with the AhR nuclear translocator (ARNT) and binds xenobiotic responsive
elements (XREs) where the AhR acts as a transcription factor for metabolizing enzymes
cytochrome P-450 1A1 and 1A2 (CYP1A1 and CYP1A2, respectively) and the AhR repressor
(AhRR) to repress further AhR signaling.
The aryl hydrocarbon receptor is an environmental sensor and mediates the detoxification
of environmental pollutants and decomposition of organic compounds that are naturally
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generated (Esser, 2012; Mimura et al., 1999; Stejskalova et al., 2011). The AhR is activated by a
variety of other exogenous and endogenous compounds, in addition to responding to xenobiotics,
with most other AhR ligands generated from metabolism of dietary compounds (Li et al., 2011;
Stejskalova et al., 2011). Ligands with the highest AhR binding affinity include toxic and
hydrophobic compounds like polycyclic aromatic hydrocarbons and halogenated dioxins
(Stejskalova et al., 2011). A photoproduct derived from L-tryptophan, 6-formylindolo[3,2-b]
carbazole (FICZ) is a high-affinity AhR ligand, however, it is rapidly metabolized (Ehrlich et al.,
2018; Rannug & Fritsche, 2006; Veldhoen et al., 2008; Zhou, 2016). The prototypical AhR
ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin, is not influenced by the xenobiotic metabolizing
enzymes generated during AhR-mediated transcription and allowing for an extended half-life
(Ehrlich et al., 2018). Exposure to TCDD elicits durable and systemic AhR signaling, contrasted
by transient and localized AhR signaling following exposure to FICZ (Ehrlich et al., 2018). The
distinction in half-life between TCDD and FICZ is further characterized by weeks of AhR
signaling following a single dose of TCDD within the µg/kg range, compared alongside hours of
AhR signaling following the same dosage using FICZ (Ehrlich et al., 2018).
Novel compounds, such as 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-otolylazo-phenyl)-amide (CH-223191) elicit antagonistic characteristics through the inhibition of
AhR-mediated transcription by blocking TCDD-AhR interactions (Kim et al., 2006; Stejskalova
et al., 2011). Inhibition of AhR-dependent transcription by CH-223191 has been shown to
prevent TCDD-mediated toxicity in a human hepatoma cell line, which was further demonstrated
using mouse models in vivo (Kim et al., 2006). Some AhR antagonists exhibit agonistic activity
when used at high concentrations, while CH-223191 has no agonist activity when used at high
concentrations (Kim et al., 2006).
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Immune Function
Innate and adaptive immune cell types have been described to be influenced by AhR
activation in ligand-, dose-, and disease-specific manners (Kimura et al., 2008; Quintana et al.,
2008; Veldhoen et al., 2008). T cell differentiation is variably influenced by AhR activation;
however, thymic atrophy is consistently observed in mice exposed to 2,3,7,8-tetrachlorodibenzop-dioxin (Chastain & Pazdernik, 1985; Clark et al., 1981). Aryl hydrocarbon receptor expression
by naïve splenic T cells has been shown to be induced in the presence of Th17-stimulating
conditions, and critical for the development of Th17 cells (Kimura et al., 2008). Helper CD4+ T
cells stimulated in vitro and exposed to FICZ has been shown to enhance Th17 cells and cytokine
production, while CD4+ T cells from AhR-deficient mice stimulated in vitro and exposed to
FICZ did not exhibit enhanced development (Veldhoen et al., 2008).
The L-tryptophan-derived photoproduct, FICZ, has been shown to accelerate the onset
and severity of experimental autoimmune encephalomyelitis which was not observed in AhRdeficient mice and was postulated to be due to AhR-mediated enhancement of Th17 cell
development (Veldhoen et al., 2008). 2,3,7,8-Tetrachlorodibenzo-p-dioxin has been shown to
have the opposite in experimental autoimmune encephalomyelitis models, as it significantly
inhibited disease severity supported by the lack of inhibition observed in AhR-deficient mice
treated with TCDD, postulated to be due to AhR-mediated enhancement of regulatory T cell
differentiation (Quintana et al., 2008). Ehrlich et al. (2018) demonstrated that the dosage of AhR
ligands, opposed to the ligand itself, determines CD4+ T cell differentiation to regulatory T or
Th17 cells (Ehrlich et al., 2018). The influence of AhR activation on CD4+ T cell differentiation
varies within disease models in a dose-rate and dose-dependent manner, generally AhR
activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin supports immunosuppression and increased
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generation of regulatory T cells (Ehrlich et al., 2018; Quintana et al., 2008; Veldhoen et al.,
2008).
Systemic T cell responses have been shown to be positively influenced by some AhR
agonists, such that, activation of the AhR is widely accepted to have potential therapeutic
benefits (Van Voorhis et al., 2013). Mice receiving mismatched skin graft transplants and
exposed to TCDD have been shown to have delayed graft rejection by several weeks, compared
alongside accelerated graft rejection when exposed to FICZ (Pauly et al., 2012). Exposure to
2,3,7,8-tetrachlorodibenzo-p-dioxin following ocular infections by viruses like the herpes
simplex virus, have been shown to decrease CD4+ T cell-mediated pathology (Veiga-Parga et al.,
2011). However, TCDD treatment in mice is more commonly associated with impaired host
resistance to viral pathogens (Fiorito et al., 2017) and has been shown to increase mortality rates
associated with influenza A infections, postulated to be a consequence of increased inflammatory
responses, with secondary contributions from suppressed antibody responses (Vorderstrasse et
al., 2003). Notably, Wheeler et al. (2014) found that mice orally administered FICZ one day
prior to infection with influenza A and once a day for seven days after infection showed no
induction of CYP1A1 levels in the lungs, contrasted by increased lung CYP1A1 levels from
mice that received an equal and single dosage of TCDD one day prior to infection (Wheeler et
al., 2014). These findings demonstrated transient AhR activation in vivo by FICZ, contrasted by
sustained AhR activation by TCDD (Wheeler et al., 2014) and further support the significance of
AhR activation influencing disease models in a dose-rate and dose-dependent manner resulting
from differential AhR ligand metabolism rates.
B cells have been shown to be differentially impacted by various AhR ligands.
Expression of the AhR by B cells is induced by BCR activation, although the level of induction
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is dependent on the BCR stimulus (Villa et al., 2017). B cells cultured under TD-conditions and
exposed to the tryptophan metabolite, 2-(1’H-indole-3’-carbonyl)-thiazole-4-carboxylic acid
methyl ester, resulted in suppressed production of some antibody isotypes, paralleled with
suppression of terminal differentiation into PCs (Yoshida et al., 2012). Aryl hydrocarbon
receptor-mediated suppression of antibody production has been supported by the finding that
AhR activation suppresses CSR through the repression of AID expression (Vaidyanathan et al.,
2017). The transcription factor, Bach2 is a key factor in repressing PC differentiation and
promoting CSR has also been shown to be an AhR target in primary mouse CD19+ cells and the
mouse B cell lymphoma cell line, CH12.LX, thereby suppressing PC differentiation (De Abrew
et al., 2010, 2011). B lymphocyte induced maturation protein 1, a positive regulator of PC
differentiation, is suppressed by TCDD in CH12.LX cells resulting in reduced B cell
differentiation (Schneider et al., 2009). Taken collectively, there is a vast amount of research
conducted regarding AhR-mediated transcriptional regulation of B cell differentiation with
limited research on AhR-mediated transcriptional regulation of B cell migration markers.
Mucosal immunity is supported by ILCs in the LP that express the retineic-acid-receptorrelated orphan nuclear receptor gamma (RORgt) and produce IL-17 and/or IL-22 providing
protection against some extracellular pathogens (Qiu et al., 2012). The AhR has been shown to
regulate IL-22 expression and consequently regulate RORgt+ ILC function (Qiu et al., 2012).
Exposure to FICZ in vivo enhanced RORgt+ ILC accumulation in the gut, while AhR-deficient
mice had significantly fewer RORgt+ ILCs (Qiu et al., 2012). Paralleled with ILCs, intraepithelial
lymphocytes contribute to barrier functions on external surfaces and mucosal surfaces (Benson &
Shepherd, 2011; Chmill et al., 2010; Li et al., 2011). Notably, intraepithelial lymphocytes

38
express high levels of the AhR and are not maintained on external or internal surfaces in the
absence of AhR activation, resulting in decreased intestinal protection (Li et al., 2011).
Inflammatory bowel disease is characterized by chronic inflammation of the
gastrointestinal tract (Benson & Shepherd, 2011). In Crohn’s disease, infiltration of some CD4+
T cell subsets and imbalanced differentiation results in Th17-skewed response (Benson &
Shepherd, 2011; Monteleone et al., 2011). Experimentally induced colitis in mouse models
through T-cell transfers, dextran sulfate sodium, and trinitrobenzene sulfonic acid (TNBS) allow
for comparisons to inflammatory responses observed in humans with inflammatory bowel
disease (Benson & Shepherd, 2011; Monteleone et al., 2011). In vivo exposure to FICZ or TCDD
has been shown to be protective against experimentally induced colitis that was paralleled with
increased expression of IL-22, consistent with findings previously described (Benson &
Shepherd, 2011; Monteleone et al., 2011; Qiu et al., 2012). Treatment with TCDD was shown to
significantly decrease the pathology of TNBS-induced colitis, paralleled with suppression of proinflammatory cytokines (Benson & Shepherd, 2011).
Antibody production within the gut, specifically IgA, regulates gut immunity; notably
80% of all ASCs are located within the gut (Benson & Shepherd, 2011; Brandtzaeg & Johansen,
2005). Benson and Shepherd (2011) found that mice exposed to 2,3,7,8-tetrachlorodibenzo-pdioxin with TNBS-induced colitis had significantly increased fecal IgA levels compared to
controls, with no significant difference observed in the serum (Benson & Shepherd, 2011). These
findings were hypothesized to be a consequence of DC- or IEC-mediated stimulation for IgACSR, although authors propose the need for further studies to determine the mechanisms by
which TCDD influences IgA-secretion in the gut (Benson & Shepherd, 2011). Interestingly,
previous results from this laboratory have shown that mice exposed to 2,3,7,8-
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tetrachlorodibenzo-p-dioxin and immunized with cholera toxin have suppressed serum levels of
CT-specific IgA compared to controls, with no significant difference observed in fecal IgA levels
at the same time point (Figure 6) (DeKrey et al., 2016; King et al., 2018). These findings suggest
that TCDD exposure differentially regulates mucosal and systemic IgA responses and were
hypothesized to be a consequence of enhanced plasma cell migration into mucosal tissues
(DeKrey et al., 2016; King et al., 2018, 2021).
Figure 6
Aryl Hydrocarbon Receptor Activation Fails to Alter Cholera Toxin-Specific IgA Secretion
Beyond the Second Week After Oral Immunization in Mice.
A
B

Note. Female C57BL/6 mice (6-10 weeks of age) were administered peanut oil (vehicle control)
or TCDD by gavage on day zero. Cholera toxin (CT) from Vibrio cholerae was administered by
gavage (10 µg per mouse) three times at ten-day intervals beginning on day one. Fecal samples
were collected weekly, serum was collected on day 28. Antibody levels were analyzed by
enzyme-linked immunosorbent assays. Data are presented as means ± SEM; n = 3-12 per
treatment group. Differences between means were considered significant at P < 0.05.
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CHAPTER III
METHODOLOGY
2,3,7,8-Tetrachlorodibenzo-p-dioxin and Cholera Toxin
2,3,7,8-Tetrachlorodibenzo-p-dioxin was obtained from Cambridge Isotope Laboratories
Inc. (Andover, MA). 2,3,7,8-Tetrachlorodibenzo-p-dioxin was diluted with 100% peanut oil
(Albertsons Companies Inc.) prior to confirmation of concentration by gas chromatography using
methods designed by Lamberton et al. (Lamberton et al., 1979) as previously described (DeKrey
et al., 2013). Whole cholera toxin (List Biological Laboratories, Campbell, CA) was prepared in
carbonate-buffered saline (Lycke et al., 1999) the day of immunization and administered by
gavage every seven days.
Mice and Tissue Processing
Female C57BL/6 mice between the ages of six and ten weeks were obtained from
breeding colonies at the University of Northern Colorado, with breeding animals purchased from
The Jackson Laboratory (Bar Harbor, ME). Animals were housed in Optimice® cages containing
Tek-Fresh bedding (Envigo, 7099) and provided with food (Envigo, Rodent Diet 2016) and
deionized water ad libitum. Animals were maintained at 72 degrees Fahrenheit in 50% humidity
on a 12-hour light/dark cycle.
Spleens were removed aseptically using toothed forceps and scissors followed by cell
liberation with frosted slides. Under aseptic conditions splenocytes were washed with RPMI
1640 (ThermoFisher Scientific, 11875093), supplemented with 10% heat-inactivated fetal bovine
serum (FBS) (HyClone, SH30071.03), 1% Penicillin Streptomycin (SigmaAldrich, P4333), 1%
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GlutaMAX (ThermoFisher Scientific, 35050079), and 50 µM 2-mercaptoethanol (SigmaAldrich,
M7522). Erythrocytes were lysed on ice by the addition of 4.5 mL ultrapure water for 10
seconds, followed immediately by the addition of 0.5 mL 10X PBS and 5 mL supplemented
RPMI 1640, samples were centrifuged (1500 rpm for 5 minutes) and resuspended in 5 mL
supplemented RPMI 1640. For experiments using sorted cells, splenocytes were further isolated
by passage through 41 µM nylon mesh (Elko Filtering Co.). Cell concentrations and viability
were determined by microscopy and trypan blue without any incubation steps (Strober, 2001).
All animal procedures were performed according to the Institutional Animal Care and Use
Committee Protocol (1812C). Mice were routinely monitored for diarrhea or other signs of
intestinal distress. Animals did not show signs of intestinal stress at any point during treatments.
Treatment with TCDD did not significantly alter body weight throughout the course of these
experiments, as previously observed (DeKrey et al., 2016).
In Vivo Experiments
Mice were randomly assigned to one of two treatment groups and orally administered
TCDD in peanut oil (0 or 40 µg/kg body weight) on day zero. On day one, all mice were orally
immunized with CT (10 µg/20 g body weight). Each subsequent week, for two or three weeks,
each mouse was administered an additional dose of CT (Figure 7) for a total of 3-4
immunizations. On the day of tissue harvest (day 28), mice were euthanized by CO2
asphyxiation.
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Figure 7
Experimental Timeline for In Vivo Experiments.

Note. Female C57BL/6 mice were randomly assigned one of two treatment groups and were
administered 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) at 40 µg/kg body weight or peanut oil
(p.o.) (controls) on day 0 prior to CT immunizations on day 1 and at 7-day intervals thereafter.
Spleens were harvested and processed on day 28 for quantification of nonspecific IgA-ASCs and
CT-specific IgA-ASCs.
Enzyme-Linked Immunosorbent
Spot Assay
Preparation of Enzyme-Linked
Immunosorbent Spot Assay
Plates
Prior to the day of tissue harvesting, enzyme-linked immunosorbent spot (ELISpot) assay
plates (MabTech, 3654-WP) were activated according to manufacturer’s protocol. Plates used for
nonspecific IgA were coated with unlabeled Goat anti-Mouse IgA (15 µg/mL) (SouthernBiotech,
1040-01) in phosphate buffered saline (PBS). Plates used for antigen-specific IgA were coated
with CT (10 µg/mL) in PBS. Coated plates were wrapped in aluminum foil to limit evaporation
and incubated overnight at 4° Celsius.
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Cell Plating
Plates were washed and blocked according to manufacturer’s protocol. Following
splenocyte isolation and counting, splenocytes for nonspecific IgA plates were cultured in
supplemented RPMI 1640 at 2.5-5.0 x 104 cells/well or 1-2 x 105 cells/well (100 µL/well) for
CT-specific IgA.
Spot Development
Spot development was performed according to manufacturer’s protocol (MabTech).
Antibody and enzyme dilutions were performed in PBS-0.5% FBS: biotinylated Goat anti-Mouse
IgA (0.5 µg/mL) and Streptavidin-Alkaline Phosphatase (0.5 x 10-3 mg/mL). The substrate, 5bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium (BCIP®/NBT Liquid Substrate
System) was added at 100 µL/well. Plates were allowed to develop until distinct spots emerged,
followed by extensive washing of the wells. Plates were left to dry in the dark at room
temperature before counting using a dissecting microscope.
In Vitro Experiments
Cell Staining
Blocking and staining of cells was performed in PAB (PBS, supplemented with 0.02%
sodium azide and 1% bovine serum albumin) (staining buffer) on ice as previously described
(Maciorowski et al., 2017). Cells were incubated with FC block (BioLegend, 101301) according
to the manufacturer’s protocol prior to staining. Cells were incubated with fluorophoreconjugated antibodies (BioLegend, unless otherwise stated) at appropriate concentrations that
were determined by titration: AF-657 anti-CD19 (115522), AF-647 anti-mouse CCR9 (128707),
PE anti-mouse LPAM-1 (120605), and FITC anti-mouse Integrin b7 (BD Biosciences, 557497).
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Cell Sorting
Fluorescence Activated Cell Sorting
Cells were diluted (10-20 x 106 cells/mL), stained with anti-CD19, and washed with
staining buffer. Splenic B cells were purified by CD19 positive selection using fluorescence
activated cell sorting (SONY SH-800) set to sort for purity above yield (Figure 8). Splenic
CD19+ cells were collected in collection buffer (PBS-30% FBS) and analyzed by flow cytometry
for purity. Collected samples were verified to be ³ 95% pure prior to counting and culturing
under IgA-stimulating conditions.
Figure 8
Fluorescence Activated Cell Sorting Gating Strategy.

Note. Representative gating strategy for sorting CD19+ splenocytes. Murine splenocytes were
sorted by CD19+ positive selection using fluorescence activated cell sorting. Collected cells were
analyzed by flow cytometry to determine purity.
Magnetic Activated Cell Sorting
Splenocytes were prepared as described above and diluted to 1 x 107 cells/mL, and B
cells were isolated using the MojoSort system (BioLegend). Biotinylated-antibody cocktail
(BioLegend, 480051) and Streptavidin Nanobeads were added according to the manufacturer’s
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protocol. Sorted cells were counted and stained for CD19 for purity verification. Collected cells
were verified to be ³ 95% CD19+ prior to culturing under IgA CSR-stimulating conditions.
B Cell Stimulation
Sorted CD19+ cells were cultured in 1 mL supplemented RPMI 1640 at 5 x 105 cells/well.
Supplemented RPMI 1640 for in vitro IgA-CSR stimulation contained 25 µg/mL LPS
(SigmaAldrich, L6529), 2 ng/mL TGF-b1 (PeproTech, 100-21), and 300 ng/mL anti-IgD-dextran
(FinaBiosolutions, 001). Cells were treated with vehicle control (0.3% DMSO), TCDD (50 nM),
CH-223191 (100 µM) (SigmaAldrich, C8124), or both TCDD and CH-223191. In experiments
using retinoic acid (SigmaAldrich, R2625), RA was added at 10 nM. Cells were cultured at 37°
Celsius in humidified air at 5% CO2 for 96 hours in the presence or absence of AhR ligands.
Flow Cytometry
Phenotype analysis of cells was performed using an Attune NxT flow cytometer
(ThermoFisher Scientific). Control samples were stained with isotype- and fluorophore-matched
antibodies. Results were analyzed using FlowJo software (version 10; BD Biosciences).
Statistical Analysis
Statistical hypothesis testing was performed using GraphPad Prism Software (version
9.3.0) or SAS (version 9.4). Multiple experiments of each design were conducted. Students T test
was used for in vivo experiments, using the Mann-Whitney test for rank comparisons between
treatment groups. Significant effects of interest (TCDD treatment) are shown here. Cells that
were obtained from different animals for in vitro experiments were cultured separately,
sometimes within a single experiment. Analysis of Variance was used for in vitro experiments to
determine which variables (experimental trial, mouse, TCDD exposure, CH-223191 exposure)
were associated with significant effects. Normality was assessed by Shapiro-Wilk tests.
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Significant effects of interest (TCDD exposure, CH-223191 exposure) are shown here.
Differences between means were considered significant at P < 0.05.
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CHAPTER IV
RESULTS
Splenic Leukocyte Numbers in Response to
2,3,7,8-Tetrachlorodibenzo-p-dioxin
Splenic leukocytes have previously been shown to be reduced in TCDD-treated mice in
the absence of CT immunizations, seven days following oral or intraperitoneal TCDD
administration (Chastain & Pazdernik, 1985; Ramos, 2019). Therefore, we predicted that splenic
leukocyte numbers would be reduced by TCDD administration in CT immunized mice also. As
shown in Figure 9, the number of total splenic leukocytes in control animals (vehicle-treated)
were comparable between three or four weekly CT immunizations. Total splenic leukocytes were
moderately reduced in TCDD treated mice with three CT immunizations by less than 20%, but
significantly reduced in TCDD-treated mice with four CT immunizations by approximately 40%.
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Figure 9
Leukocytes Decrease in the Spleens of TCDD-Treated Mice.

Note. Female C57BL/6 mice were immunized with CT and treated with TCDD, or vehicle as
described in Methods. Leukocyte numbers were determined by trypan blue exclusion and are
presented as the total number of live leukocytes per spleen. (A) Leukocyte numbers after three
CT immunizations; n = 6 per treatment group. (B) Leukocyte numbers after four CT
immunizations; n = 4 per treatment group. The data represent means ± SEM; *, P < 0.05.
Immunoglobulin A-Producing Cells
Total serum IgA levels in CT-immunized mice have been shown to be significantly
suppressed four weeks after TCDD treatment in comparison to vehicle-treated mice (DeKrey et
al., 2016; King et al., 2018, 2021). Therefore, in CT-immunized mice, we predicted the total
number of splenic IgA-ASCs would be decreased by exposure to 2,3,7,8-tetrachlorodibenzo-pdioxin. As shown in Figure 10, the number of IgA-expressing cells at 28 days in control animals
ranged from approximately 50,000 after three CT immunizations to approximately 40,000 after
four CT immunizations. Whether mice received three or four CT immunizations, the number of
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IgA-expressing cells were significantly reduced in TCDD-treated mice by 60% or more at day
28.
Figure 10
Immunoglobulin A-Expressing Spleen ASC Numbers were Decreased Following TCDD
Treatment.

Note. Female C57BL/6 mice were immunized with CT and treated with TCDD, or vehicle as
described in Methods. Immunoglobulin A-ASC numbers were determined by ELISpot and are
presented as the total number of IgA expressing cells per spleen. (A) Antibody-secreting cell
numbers after three CT immunizations; n = 6 per treatment group. (B) Antibody-secreting cell
numbers after four CT immunizations; n = 4 per treatment group. The data represent means ±
SEM; *, P < 0.05.
Antigen-Specific Immunoglobulin A-Producing Cells
In cholera toxin-immunized mice, CT-specific serum IgA levels have been shown to be
significantly suppressed four weeks after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin
when compared to vehicle-treated animals (King et al., 2021). We predicted that suppression of
serum CT-specific IgA levels in TCDD-treated mice would be paralleled with significant
reductions in the number of CT-specific IgA-expressing cells in TCDD-treated mice. As shown
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in Figure 11, approximately 4500 CT-specific IgA-expressing cells were found per spleen in
control animals. In contrast, approximately 150 CT-specific IgA-expressing cells were found per
spleen in TCDD-treated animals, but this difference was found to be not significant (P = 0.0909).
Figure 11
Cholera Toxin-Specific Spleen IgA-ASC Numbers were Reduced, but not Significantly, by TCDD
Exposure.

Note. Female C57BL/6 mice were immunized with CT and treated with TCDD, or vehicle as
described in Methods. Cholera toxin-specific IgA-ASC numbers were determined by ELISpot
four weeks after treatment. The data represent means ± SEM for six animals per treatment group.
Gut-Homing Marker Expression on
Murine Splenic B Cells
CD19+ Purity Analysis
Following negative or positive selection for splenic B cells, the purity of isolated B cells
was determined by flow cytometry. As shown in Figure 12, greater than 95% of the cells isolated
by positive selection or negative selection were CD19+ B cells.
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Figure 12
Representative Flow Cytometric Analysis of Sorted CD19+ Spleen Cells.

Note. Murine splenocytes were sorted by (A) expression of CD19 (positive selection) using
fluorescence activated cell sorting and (B) negative selection using magnetic activated cell
sorting. Sorted cells (right) were analyzed by flow cytometry to confirm ³ 95% purity compared
alongside the appropriate isotype control (left).
Expression of a4b7 Integrin is
Measurable and can be
Upregulated on
Activated B
Cells
To determine that a4b7 integrin was measurable in our model, we activated CD19+
spleen cells in the presence of exogenous retinoic acid. As shown in Figure 13, RA exposure
markedly increased surface expression of a4b7 integrin as well as expression frequency.

52
Figure 13
B Cell Exposure to Retinoic Acid Increases Expression of a4b7 Integrin.

Note. Murine CD19+ splenocytes were activated as described in Methods to stimulate IgA-CSR
and exposed to vehicle (DMSO) or retinoic acid (RA). After four days, viable cells were
analyzed by flow cytometry (A) Percent a4b7 integrin expression. (B) Mean fluorescence
intensity for a4b7 integrin on a4b7 integrin-expressing cells. The data represent means ± SEM,
n = 1-8 per treatment group. Mean fluorescence intensity, MFI.
CD19+ Spleen Cell Viability and
Recovery in the Presence of
Aryl Hydrocarbon
Receptor Ligands
Proliferation and differentiation of cultured B cells is known to be negatively influenced
in the presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (Vaidyanathan et al., 2017). Therefore, we
predicted that cell viability and cell number recovery after four days of culture would increase in
the presence of an AhR antagonist, CH-223191, when compared to either vehicle-exposed cells
or cells cultured with TCDD. As shown in Figure 14, in vehicle-exposed cultures (DMSO, no
activation), B cell viability after four days was approximately 20% with a recovery of
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approximately 11% relative to an initial 500,000 cells added per culture. When cells were
exposed to vehicle and activated (control cultures), cell viability increased approximately twofold (not significant) and cell recovery increased by over five-fold (not significant). When
activated cells were exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin, cell viability declined
slightly compared to control cultures and the increased recovery was largely lost. When activated
cells were exposed to CH-223191, in comparison to TCDD cultures, cell viability and recovery
increased by approximately two-fold, but this effect was found to be not significant. When
activated cells were exposed to both TCDD and CH-223191, cell viability slightly decreased
compared to CH-223191 cultures, with an approximate two-fold decrease in cell recovery.
Figure 14
In Vitro CD19+ Spleen Cell Survival is Influenced by the Presence of AhR Ligands.

Note. Murine CD19+ splenocytes were activated as described in Methods to stimulate IgA-CSR
and exposed to vehicle or AhR ligands at 5 x 105 cells per culture. Activated CD19+ splenocytes
cultured with vehicle and without exogenous AhR ligands are shown for comparison against
nonactivated CD19+ splenocytes exposed to vehicle only. After 4 days, viability (A) and
recovered viable cells (B) were determined by trypan blue exclusion. Data represents mean ±
SEM; n = 2-6 per treatment group. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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As shown in Figure 15, in cultures of activated cells exposed to vehicle and CH-223191
alone (white bars), B cell viability after four days was approximately 50% with a recovery of
approximately 60%. When activated cells were exposed to either TCDD or both TCDD and CH223191 (black bars), cell viability significantly decreased compared to cultures that did not
contain TCDD (P = 0.0092). When activated cells were exposed to either TCDD and both TCDD
and CH-223191, cell recovery decreased significantly by approximately two-fold compared to
vehicle and CH-223191 cultures (P = 0.0059).
Figure 15
In Vitro CD19+ Spleen Cell Survival is Negatively Influenced by TCDD Exposure.

Note. Data shown in Figure 13 were used here to present analysis of the effect of TCDD on
viability and recovery. Activated CD19+ splenocytes cultured without TCDD (white bars, pooled
data for cultures with and without CH-223191) are shown compared to activated CD19+
splenocytes cultured with TCDD (black bars, pooled data for cultures with and without CH223191). After 4 days, viability (A) and recovered viable cells (B) were determined by trypan
blue exclusion. Data represents mean ± SEM; n = 12 per treatment group. *, P < 0.05.

55
As shown in Figure 16, in cultures of activated cells exposed to vehicle and TCDD alone
(white bars), B cell viability after four days was approximately 30% with a recovery of
approximately 40%. When activated cells were exposed to either CH-223191 or both CH223191 and TCDD (grey bars), cell viability significantly increased compared to cultures that did
not contain CH-223191 (P < 0.0001). When activated cells were exposed to either CH-223191 or
both CH-223191 and TCDD, cell recovery modestly increased compared to cultures that did not
contain CH-223191, but this effect was found not to be significant (P = 0.1598).
Figure 16
In Vitro CD19+ Spleen Cell Viability, but not Recovery, is Positively Influenced by CH-223191
Exposure.

Note. Data shown in Figure 13 were used here to present analysis of the effect of CH-223191 on
viability and recovery. Activated CD19+ splenocytes cultured with vehicle or TCDD alone
(white bars) are shown for comparison against activated CD19+ splenocytes exposed to either
CH-223191 alone or both CH-223191 and TCDD (grey bars). After 4 days, viability (A) and
recovered viable cells (B) were determined by trypan blue exclusion. Data represents mean ±
SEM; n = 12 per treatment group. ***, P < 0.0001.
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Altered Expression of Gut-Homing
Markers in Response to Aryl
Hydrocarbon Receptor
Ligand Exposure
In previous studies in this laboratory, it was found that exposure to 2,3,7,8tetrachlorodibenzo-p-dioxin could suppress the fecal and serum CT-specific antibody responses
in female mice, but fecal IgA levels recovered more than a week sooner than did serum levels.
Because some T cells are known to favor migration into gut tissues after AhR activation, and
because TCDD exposure reduced the number of splenic IgA-ASCs (Figure 10), we hypothesized
that the early faster recovery of fecal IgA levels in TCDD-treated mice could be explained by
enhanced migration of ASCs away from systemic tissues (e.g., spleen) and into the gut. If this
hypothesis is true, we predicted that the expression of gut-homing markers would be increased
on activated B cells following AhR activation.
As shown in Figure 17A, the percentage of a4b7 integrin expressing cells increased (not
significant) in TCDD cultures compared to control cultures. When activated cells were exposed
to CH-223191, the percentage of a4b7+ cells decreased approximately six-fold compared to
TCDD cultures. When cells were activated and exposed to TCDD and CH-223191, the
percentage of a4b7+ cells slightly decreased approximately four-fold compared to TCDD
cultures and with a slight increase (not significant) compared to CH-223191 cultures. As shown
in Figure 17D, activated cells exposed to vehicle or AhR ligands, had similar levels of a4b7
integrin surface expression. As shown in Figure 17B, activated cells exposed to TCDD had an
approximate two-fold increase in the percentage of b7 integrin+ cells compared to control
cultures, but this difference was found not to be significant (P = 0.071). When cells were
activated and exposed to CH-223191, the percentage of b7 integrin+ cells decreased significantly
by over five-fold compared to TCDD cultures (P = 0.0015). When activated cells were exposed
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to both TCDD and CH-223191, the percentage of b7 integrin+ cells decreased approximately
four-fold compared to TCDD cultures. As shown in Figure 17E, when activated cells were
exposed to TCDD, the level of b7 integrin surface expression decreased approximately two-fold
compared to control cultures (not significant). The level of surface expression of b7 integrin on
activated cells exposed to CH-223191 significantly increased when compared to control cultures
(P = 0.0095) and increased by approximately two-fold compared to TCDD cultures (not
significant). When cells were exposed to both TCDD and CH-223191, the level of surface
expression of b7 integrin increased approximately three-fold when compared to TCDD cultures.
As shown in Figure 17C, when cells were activated and exposed to 2,3,7,8-tetrachlorodibenzo-pdioxin, the percentage of CCR9 expression cells was comparable to controls. Activated cells
exposed to CH-223191 had an approximate five-fold reduction in the percentage of CCR9+ cells
compared to TCDD cultures. Similarly, when cells were activated and exposed to TCDD and
CH-223191, the percentage of CCR9+ cells decreased approximately three-fold compared to
control and TCDD cultures. As shown in Figure 17F, activated cells exposed to TCDD had
similar levels of CCR9 surface expression compared to control cultures. When activated cells
were exposed to CH-223191, the level of surface expression of CCR9 decreased approximately
two-fold compared to TCDD cultures. When activated cells were exposed to TCDD and CH223191, the level of CCR9 surface expression increased approximately two-fold compared to
CH-223191 cultures, with comparable CCR9 surface expression to TCDD cultures.
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Figure 17
Activation of the AhR Influences Gut-Homing Marker Expression on Activated Mouse B Cells.

Note. Murine CD19+ splenocytes were activated as described in Methods. Activated CD19+
splenocytes cultured with vehicle (control) are shown for comparison. After 4 days, viable cells
were analyzed by flow cytometry. (A) Percent a4b7 integrin expression. (B) Percent b7 integrin
expression. (C) Percent CCR9 expression. (D) Mean fluorescence intensity for a4b7 integrin on
a4b7-expressing cells. (E) Mean fluorescence intensity for b7 integrin on b7 integrin-expressing
cells. (F) Mean fluorescence intensity for CCR9 on CCR9-expressing cells. The data represent
means ± SEM; n = 2-6 per treatment group. Mean fluorescence intensity, MFI. *, P < 0.05; **, P
< 0.01; ***, P < 0.001.
As shown in Figure 18A, the percentage of a4b7+ cells in cultures of activated cells
exposed to vehicle and CH-223191 alone (white bars) was slightly lower compared cultures of
activated cells that contained 2,3,7,8-tetrachlorodibenzo-p-dioxin (black bars), but this effect was
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not found to be significant. Similarly, as shown in Figure 18D, we did not observe an increase in
the level of a4b7 integrin expression when cells were activated in the presence of TCDD
compared to cultures that did not contain TCDD. However, as shown in Figure 18B, the
percentage of b7 integrin+ cells significantly increased when cells were activated in the presence
of TCDD (P = 0.0186), this was contrasted by a decrease (not significant) of the level of b7
integrin expression in cultures containing TCDD (Figure 18E). As shown in Figure 18C, the
percentage of CCR9 expressing cells did not significantly differ between cultures that did not
contain TCDD and cultures that contained TCDD. However, in cultures containing TCDD, we
observed a significant increase in the level of CCR9 expression compared to cells activated
without TCDD (P = 0.0232) (Figure 18F).
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Figure 18
Exposure to TCDD Differentially Regulates the Expression of Gut-Homing Markers on Murine
CD19+ Splenocytes.

Note. Data shown in Figure 17 were used here to present analysis of the effect of TCDD on the
expression of gut-homing markers. Activated CD19+ splenocytes cultured with vehicle or CH223191 alone (white bars) are shown for comparison against activated CD19+ splenocytes
exposed to either TCDD alone or both TCDD and CH-223191 (black bars). (A) Percent a4b7
integrin expression. (B) Percent b7 integrin expression. (C) Percent CCR9 expression. (D) Mean
fluorescence intensity for a4b7 integrin on a4b7-expressing cells. (E) Mean fluorescence
intensity for b7 integrin on b7 integrin-expressing cells. (F) Mean fluorescence intensity for
CCR9 on CCR9-expressing cells. The data represent means ± SEM; n = 2-6 per treatment group.
Mean fluorescence intensity, MFI. *, P < 0.05.
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As shown in Figure 19A, the percentage of a4b7+ expressing cells from cultures
activated with CH-223191 and TCDD or CH-223191 alone (grey bars) was significantly reduced
compared to cultures that did not contain CH-223191 (white bars) (P = 0.0004). This observation
was contrasted with no significant impact on the level of a4b7 integrin expression between
cultures that contained CH-223191 and cultures without CH-223191 (Figure 19D). As shown in
Figure 19B, when cells were activated in the presence of CH-223191 there was a significant
reduction in the percentage of b7 integrin+ cells compared to cultures that did not contain CH223191 (P = 0.0001). However, cells activated in cultures containing CH-223191 had a
significantly increased level of b7 integrin expression compared to cells activated without CH223191 (P = 0.0009) (Figure 19E). As shown in Figure 19C, cultures containing CH-223191 had
a significant reduction in the percentage of CCR9+ cells compared to cultures that did not contain
CH-223191 (P = 0.0008), paralleled by a modest, but not significant, decrease in the level of
CCR9 expression on CCR9 expressing cells (Figure 19F).
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Figure 19
Expression of Gut-Homing Markers is Negatively Regulated by CH-223191 Exposure, but not
the Level of Expression, on Murine CD19+ Splenocytes.

Note. Data shown in Figure 17 were used here to present analysis of the effect of CH-223191 on
the expression of gut-homing markers. Activated CD19+ splenocytes cultured with vehicle or
TCDD alone (white bars) are shown for comparison against activated CD19+ splenocytes
exposed to either CH-223191 alone or both CH-223191 and TCDD (grey bars). (A) Percent
a4b7 integrin expression. (B) Percent b7 integrin expression. (C) Percent CCR9 expression. (D)
Mean fluorescence intensity for a4b7 integrin on a4b7-expressing cells. (E) Mean fluorescence
intensity for b7 integrin on b7 integrin-expressing cells. (F) Mean fluorescence intensity for
CCR9 on CCR9-expressing cells. The data represent means ± SEM; n = 2-6 per treatment group.
Mean fluorescence intensity, MFI. ***, P < 0.001.
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CHAPTER V
DISCUSSION AND CONCLUSIONS
Spleen Cellularity in Response to 2,3,7,8Tetrachlorodibenzo-p-dioxin
Our findings of decreased spleen cells in TCDD-treated, CT-immunized mice (Figure 9)
are supported by previous findings of decreased spleen cellularity in mice exposed to 2,3,7,8tetrachlorodibenzo-p-dioxin (Chastain & Pazdernik, 1985; DeKrey & Kerkvliet, 1995;
Vorderstrasse et al., 2001). Chastain and Pazdernik (1985) demonstrated significant decreases in
the number of spleen cells from male C57BL/6 mice seven days after TCDD administered via
intraperitoneal (i.p.) injection (Chastain & Pazdernik, 1985). Notably, decreased spleen cell
numbers were observed in mice that received TCDD at a dosage of either 30 or 60 µg/kg body
weight (Chastain & Pazdernik, 1985), like our findings using a dosage of 40 µg/kg body weight,
through alternative routes of administration. In addition, Chastain and Pazdernik (1985) found
significantly decreased spleen cellularity 14 and 21 days after i.p. TCDD injection, although at a
dosage of 120 µg/kg body weight. However, these findings were suggested to be due to
decreased bone marrow cellularity, resulting in decreased spleen cell repopulation (Chastain &
Pazdernik, 1985). Notably, significant reductions in bone marrow cellularity seven days after
TCDD administration was not observed in mice exposed to TCDD at 30 or 60 µg/kg body
weight (Chastain & Pazdernik, 1985). It is possible that our observations of decreased spleen
cellularity are partially due to the influence of 2,3,7,8-tetrachlorodibenzo-p-dioxin on early B
cell development in the bone marrow, however the studies done by Chastain and Pazdernik
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(1985) were conducted under alternative settings, including the dosage and route of TCDD
administration, animal gender, and experimental end points.
DeKrey and Kerkvliet (1995) demonstrated significant reductions in spleen cells from
male C57BL/6 mice administered TCDD orally one day prior to i.p. injections with allogeneic
P815 tumor cells compared alongside vehicle-treated control mice (DeKrey & Kerkvliet, 1995).
Notably, these reductions in spleen cells were found to be significantly different from vehicletreated mice ten days following challenge with P815 cells at each dosage of TCDD (2.5-40
µg/kg body weight) administered (DeKrey & Kerkvliet, 1995). Vorderstrasse et al. (2001)
observed a similar and significant reduction in spleen cells from wild-type C57BL/6 mice ten
days after P815 challenge via i.p. injection that had been administered a single oral dose of
TCDD (15 µg/kg) one day prior to P815 challenge (Vorderstrasse et al., 2001). Further,
Vorderstrasse et al. (2001) did not observe a significant reduction in total spleen cell numbers
from AhR-deficient mice of C57BL/6 background exposed to TCDD and challenged with P815
tumor cells. Despite the negative influence of AhR activation on splenic cellularity in wild-type
mice that was not observed in AhR-deficient mice, Vorderstrasse et al. (2001) demonstrated that,
in the absence of TCDD, AhR-deficient mice mounted comparable immune responses to wildtype animals when challenged with allogeneic tumor cells (Vorderstrasse et al., 2001). These
findings suggest that expression of the aryl hydrocarbon receptor is not required for immune
system development, but when activated, plays a critical role in systemic immunosuppression.
Because decreased spleen cellularity in mice has been widely observed following
exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin at doses that do not alter bone marrow
cellularity, we predicted significant reductions in splenic leukocytes from mice exposed to
TCDD in this study, a prediction that was confirmed (Figure 9). To explain this observation, we
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hypothesized that AhR activation enhances the migration of plasma cells away from
reticuloendothelial tissues and into mucosal tissues. This potential behavior of B cells is
supported by the observation that some subsets of T cells display enhanced migration to
locations within GALT following AhR activation (Ehrlich et al., 2017). It is possible that
migration of T cells led to the observed reductions of total spleen cell numbers in our model
(Figure 9) because T cells account for approximately 20-25% of murine spleen cells. However,
murine spleens contain approximately 40-60% B cells. Given that TCDD-treated mice contained
40.4% fewer leukocytes than control mice (Figure 9), it is unlikely that the change we observed
was solely due to T cell migration. Additionally, significant reductions in splenic IgA-ASC
numbers from TCDD-treated mice compared alongside controls would contribute to overall
reductions in total spleen cell numbers from TCDD-treated mice.
Immunoglobulin A-Producing Cells
Oral challenge with CT is one of the most well studied oral antigen challenges and elicits
a robust IgA response in the intestines (Elson & Ealding, 1984). Stimulation of immune
responses within the gut due to CT-immunization is known to increase IgA-ASC numbers in the
gut of mice. Activation of the AhR with 2,3,7,8-tetrachlorodibenzo-p-dioxin can suppress
antibody responses in mice (Dooley & Holsapple, 1988), and this has been shown to also occur
for anti-CT antibody responses measured in both the serum and feces (King et al., 2018, 2021).
However, recovery from this suppression has been shown to be biased, with antibody levels in
feces recovering to control levels at least a week earlier than those in serum (King et al., 2018,
2021). Because some T cell populations are known to migrate to the gut in larger numbers after
AhR activation, we hypothesized that activation of the AhR increases B cell migration to the gut.
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Our hypothesis was supported by the marked reduction of splenic nonspecific IgA-ASCs we
observed in CT-immunized mice treated with TCDD (Figure 10).
We predicted that TCDD exposure would significantly reduce CT-specific IgA-ASC
numbers in the spleen, relative to control animals, at a time when fecal CT-specific antibody
levels had fully recovered. As shown in Figure 11, our prediction was correct because TCDD
exposure decreased CT-specific IgA-ASCs from approximately 4500 in controls to
approximately 150. However, this difference was not statistically significant (Figure 11).
Collectively, this finding does not argue against the possibility that AhR activation positively
regulates B cell migration to the gut.
Endogenous Aryl Hydrocarbon Receptor Ligands
Cell culture medium contains the essential amino acid, tryptophan, which is highly
susceptible to photolytic destruction, resulting in the formation of the tryptophan metabolite,
FICZ, a high-affinity AhR ligand (Öberg et al., 2005; Rannug & Fritsche, 2006; Veldhoen et al.,
2009). Veldhoen et al. (2009) demonstrated the influence of endogenous AhR ligands in culture
medium and found that endogenous ligands in culture medium positively influence the
differentiation of Th17 cells with inhibition of Th17 differentiation in the presence of CH-223191
(Veldhoen et al., 2009). The AhR antagonist, CH-223191, has been shown to directly block the
binding of TCDD to the AhR, with no agonist activity at high concentrations, CH-223191 is
suggested to be a specific antagonist of the AhR (Kim et al., 2006). This specificity is further
supported by the findings of inhibited Th17 differentiation in the presence of CH-223191 without
the exogenous addition of AhR agonists (Veldhoen et al., 2009). Because of this, we must
consider endogenous AhR ligands present in our culture system as co-factors contributing to
AhR activation, while the addition of CH-223191 would allow for inhibition of both AhR

67
activity resulting from endogenous ligands and the exogenous addition of 2,3,7,8tetrachlorodibenzo-p-dioxin (Figure 20).
Figure 20
Proposed Influence of CH-223191 and TCDD on AhR Activity in Murine CD19+ Cells.

Note. In this proposed model, the endogenous presence of tryptophan in culture medium results
in moderate activation of the AhR (denoted by, *) due to the formation of FICZ following light
exposure (denoted by, flashing arrow) (Veldhoen et al., 2009). In the presence of CH-223191,
AhR activation resulting from FICZ is inhibited (denoted by, %), resulting in no activation of the
AhR. The exogenous addition of TCDD allows for AhR activation, simultaneously influenced by
the presence of endogenous AhR ligands (e.g., FICZ), promoting high AhR activation. The
addition of TCDD and CH-223191 inhibits high AhR activation by TCDD exposure (denoted by,
$), in addition to inhibiting FICZ-mediated AhR activity.
B Cell Viability and Recovery in the Presence of
Aryl Hydrocarbon Receptor Ligands
In culture, without the addition of stimulating reagents, B cell viability declines rapidly.
A marked loss of non-activated B cell viability over a four-day culture period was observed in
this study (Figure 14A). In contrast, B cell activation in a T cell-independent manner (as used
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here) leads to polyclonal expansion, class switch recombination, and secretion of antibodies
(Cerutti, 2008; Montes et al., 2007; Schroeder & Cavacini, 2010; Vaidyanathan et al., 2017). Our
results (Figure 14) demonstrate the same phenomena. Previous studies have reported that B cell
differentiation can be inhibited by AhR activation (De Abrew et al., 2011; Dooley & Holsapple,
1988; Holsapple et al., 1986; North et al., 2009; Vaidyanathan et al., 2017; Zhang et al., 2013).
As shown in Figure 14, we observed that exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin
reduced the viability and number of cells recovered from activated B cell cultures when
compared to vehicle-exposed cultures, as would be expected if differentiation was inhibited.
Complemented with enhanced viability of CD19+ spleen cells exposed to CH-223191, and
comparable viability when cells were exposed to both CH-223191 and TCDD.
Given that recovery was similar between controls and groups exposed to both TCDD and
CH-223191 (Figure 20), it is possible that the negative influence of AhR activation with TCDD
on B cell survival was inhibited in the presence of CH-223191 (Kim et al., 2006; Stejskalova et
al., 2011). Because cells activated in the presence of TCDD had significantly lower viability and
recovery than cells activated in the absence of TCDD (Figure 15), the antagonistic effects on the
AhR by CH-223191 may promote B cell survival. This is supported by the significantly
increased viability of cells exposed to CH-223191 compared to controls (Figure 16A), however
recovery was not significantly enhanced by CH-223191 exposure (P = 0.1598), as shown in
figure 16B. Therefore, conclusions regarding the influence of AhR activation on splenic CD19+
cell viability and recovery in our model requires further examination.
Gut-Homing Markers in Response to Aryl Hydrocarbon
Receptor Ligands
Transfer studies conducted with CD4+ T cells have shown increased expression of some
gut migration molecules and migration to the lamina propria from mice treated with 2,3,7,8-
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tetrachlorodibenzo-p-dioxin (Ehrlich et al., 2017). These findings by Ehrlich et al. (2017) suggest
that AhR activation positively regulates CD4+ T cell migration to the gut (Ehrlich et al., 2017).
Because CT-immunized, TCDD treated mice showed decreased splenic IgA-ASCs when
compared to CT-immunize mice only, we hypothesized that activation of the AhR in B cells
leads to upregulation of gut migration markers, specifically, a4b7 integrin, b7 integrin, and
CCR9. As shown in Figure 17A-C, CD19+ splenocytes activated in the presence of TCDD had
slightly increased percentages of cells expressing a4b7 integrin, b7 integrin, and CCR9
compared to control cultures, but this effect was found not to be significant for all markers
analyzed. However, cells activated in the presence of the AhR antagonist, CH-223191
significantly decreased the percentage of cells expressing a4b7 integrin, b7 integrin, and CCR9
compared to cultures containing TCDD. These findings were contrasted by similar a4b7 integrin
surface expression between all groups analyzed (Figure 17D). Unexpectedly, cells activated in
the presence of CH-223191 had significantly increased surface expression of b7 integrin when
compared to control cultures (Figure 17E). The surface expression of CCR9 was significantly
reduced in cultures containing CH-223191 when compared to cultures containing either TCDD
or TCDD and CH-223191 (Figure 17F). Cultures containing TCDD modestly increased the
surface expression of CCR9 when compared to control cultures, but this effect was found not to
be significant. Collectively, these findings do not argue against the possibility that the AhR
contributes to regulating B cell migration to the gut.
Integrin a4b7 and b7
As shown in Figure 13, exogenous addition of RA into the culture system used here
markedly increased the percentage of a4b7 integrin expressing CD19+ splenocytes and surface
expression of a4b7. Culture medium is estimated to have trace amounts of RA due to the
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addition of animal serum. Kang et al. (2011) activated naïve CD4+ T cells in the presence RA or
Ro41-5253, a RA receptor antagonist, to determine the influence of serum-derived RA on Itg-

a4, Itg-b7, Itg-b1 transcription (Kang et al., 2011). Results demonstrated that Itg-a4
transcription is enhanced in the absence of Ro41-5253 by serum-derived RA, with further
increases in the presence of exogenous RA, contrasted with no impact on Itg-b1 or Itg-b7
transcription (Kang et al., 2011). Because of the marked increase of a4b7 integrin surface
expression by exogenous addition of RA (Figure 13) and similar levels of a4b7 integrin surface
expression we observed between treatment groups (Figure 17D), any influence from serumderived RA on Itg-a4 transcription in our culture system was not predicted to be significant.
Studies by Ehrlich et al. (2017) showed downregulation of a4 integrin on alloresponding
CD4+ T cells in response to TCDD (Ehrlich et al., 2017). Because of this, it is possible that the
similar surface expression of a4b7 integrin between the treatment groups (Figure 17D) was a
consequence of limited access to a4 integrin (Figure 21). Alternatively, it is possible that a4
preferentially dimerized with b1 integrin opposed to b7 integrin within the endoplasmic
reticulum (Figure 21). On CD4+ T cells, a4 integrin has been shown to preferentially dimerize
with b1 integrin opposed to b7 integrin (DeNucci et al., 2010). Postigo et al. (1993) observed
that activated human tonsillar B cells demonstrated greater association of a4 integrin and b1
integrin when compared to a4b7 integrin in a time-dependent manner (Postigo et al., 1993). This
finding was observed over a three-day culture period, in which expression of a4 peaked on day
three and associated with both b1 and b7 (Postigo et al., 1993). Because of this observation, it is
possible that by day four in our model, the maximum level of a4 expression had been reached,
resulting in no alterations to the surface expression of a4b7 integrin (Figure17D).
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Figure 21
Proposed Differential Influence of AhR Activity on the Expression of Integrins a4, b1, and b7 on
CD19+ Cells.

Note. Our results suggest that AhR activation positively contributes to the transcriptional
regulation of b7 integrin. While inhibition of the AhR positively regulates b7 integrin
translation. Because RA has been shown to be required for the induction of a4 integrin
transcription in CD4+ T cells (Kang et al., 2011), it is possible that expression of a4 integrin had
reached maximum expression without exogenous addition of RA. Alternatively, because we did
not observe a change in the surface expression of a4b7 integrin and because a4 integrin has
been shown to be a limiting factor with preferential association with b1 integrin (Postigo et al.,
1993), we would hypothesize that transcription of a4 integrin is negatively regulated by AhR
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activity. Because the level of a4b7 integrin expression was not altered, we would not predict any
significant influence of AhR activity on b1 integrin expression in our model.
When cells were activated in the presence of CH-223191, the percentage of a4b7 integrin
expressing cells significantly decreased compared to TCDD cultures (Figure17A), suggesting
that antagonism of the AhR with CH-223191 contributes to the regulation of a4b7 integrin
expression to a greater extent than agonism of the AhR with TCDD. This finding was further
supported by modest increase in the percentage of a4b7 integrin expressing cells when activated
in the presence of TCDD (Figure18A), but a significant reduction in the percentage of a4b7
integrin expressing cells when exposed to CH-223191 (Figure19A). However, exposure to
TCDD significantly increased the percentage of b7 integrin expressing cells (Figure18B).
Findings from McMillan et al. (2007) demonstrate a TCDD-dependent effect on the expression
of b7 integrin on early thymocytes through AhR-mediated induction of Krupple-like factor 2,
that regulates b7 integrin (McMillan et al., 2007). Paralleled with findings in macrophages that
have been shown to increase mRNA of b7 integrin in vitro when exposed to 2,3,7,8tetrachlorodibenzo-p-dioxin (Monteiro et al., 2007). Similarly, we observed a significant increase
in the percentage of b7 integrin expressing cells in groups exposed to TCDD (Figure 18B).
Unexpectedly, we also observed significantly increased b7 integrin surface expression from
cultures exposed to CH-223191 compared to cultures containing TCDD (Figure 17E). This
finding was contrasted by significant reductions in the percentage of cells expressing b7 integrin
from cells exposed to CH-223191 compared to TCDD cultures (Figure 17B). Therefore, it is
possible that antagonism or agonism of the AhR separately and differentially regulates the
expression of both a4 and b7 integrin.
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Chemokine Receptor 9
Chemokine receptor 9 is critical for intestinal IgA responses and the migration of IgAproducing cells to the small intestine (Pabst et al., 2004). Chemokines promote lymphocyte
adhesion through inducing conformational changes promoting the activation of integrins (Sun et
al., 2014). Notably, this is observed with the chemokine ligand for CCR9, CCL25, which has
been shown to promote the activation of integrin a4b7 allowing for B cell adhesion to
MAdCAM-1 in vitro (Sun et al., 2014), supporting the role of CCR9 expression for B cell for
intestinal migration through the activation of integrin a4b7. Previous studies have shown that
activation of the aryl hydrocarbon receptor positively contributes to the transcriptional regulation
of CCR9 on CD4+ T cells (Ehrlich et al., 2017). Our results support a similar conclusion, CD19+
splenocytes activated in the presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin had a modest
increase in the percentage of CCR9 expressing cells (not significant) and significantly increased
surface expression of CCR9 (Figures 18C and F). This finding was paralleled by significant
reductions in the percentage of CCR9 expressing cells with slightly decreased surface expression
of CCR9 on cells activated in the presence of the AhR antagonist, CH-223191 (Figures 19C and
F). Agonism of the AhR in our model did not significantly contribute to the level of a4b7
integrin expression (Figure 17D), however, we observed a significant increase in the level of
CCR9 surface expression (Figure 18F). These findings collectively suggest that AhR activation
with TCDD would enhance the activation of a4b7 integrin molecules due to the positively
influence on the surface expression of CCR9, thereby promoting B cell adherence to the
intestinal endothelium. However, conclusions regarding the influence CCR9-mediated activation
of a4b7 integrin on CD19+ cells in our model requires further examination.

74
Conclusion and Summary
Suppression of humoral immune responses by AhR agonists has been demonstrated
(Cervantes-Barragan & Colonna, 2018; Sulentic & Kaminski, 2011). While many studies have
been conducted on T cells in response to different AhR ligands (Ehrlich et al., 2017, 2018; Ye et
al., 2017), the immunosuppressive effects of AhR ligands vary in ligand-, dose-, and diseasespecific manners (Cervantes-Barragan & Colonna, 2018). We have demonstrated an AhRmediated effect on spleen IgA-producing cell quantity and expression of adhesion molecules
related to gut-homing on CD19+ splenic cells in our model. Collectively, our data suggest AhRmediated enhancement of B cell gut-homing. While this suggests enhancement of IgA-mediated
protection in the gut, it is possible that this results in decreased IgA-mediated protection in other
systemic locations. Therefore, further studies are warranted to gain a greater understanding of the
various AhR-mediated mechanisms on B cells and other cell types to promote the development
of therapeutic applications with desired outcomes.
The aryl hydrocarbon receptor plays a pivotal role in immune system development, in
addition to contributing to homeostatic maintenance of reproductive and cardiovascular systems
(Fernandez-Salguero et al., 1995; Shivanna et al., 2022). Ligands for the AhR are diverse and
ubiquitous, ranging from exogenous ligands such as environmental pollutants to endogenous
metabolites from dietary compounds (Shivanna et al., 2022). Because physiological AhR activity
plays crucial roles in immune system development and homeostatic maintenance, characterizing
its influence on the modulation of lymphocytic function and localization is of particular interest
for the treatment of immune-mediated diseases (Ehrlich & Kerkvliet, 2017; Esser, 2012). For
example, immune-mediated diseases like Crohn’s disease have been shown to be effectively
treated through modulating intestinal lymphocytic localization (Habtezion et al., 2016; Poole,
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2014). However, these treatments have been reported to adversely influence immune system
function at other nonintestinal mucosal and systemic compartments (Bloomgren et al., 2012;
Poole, 2014). The development of targeted therapeutic options that alter lymphocytic migration
through modulating AhR activity, such that systemic immunosuppression is less pronounced,
necessitates the characterization of the mechanisms by which AhR activity influences the
trafficking of all lymphocytic populations.
Future Studies
Intestinal Immunoglobulin
A-Producing Cells
In these studies, the influence of TCDD exposure in CT-immunized mice on the quantity
of nonspecific- and CT-specific IgA-ASCs in the spleen was determined. We have previously
found significant suppression of CT-specific IgA in the serum of TCDD-treated mice at four
weeks, while fecal CT-specific IgA was similar between TCDD-treated, CT-immunized mice
and CT-immunized mice only (King et al., 2021). Because antibody-production on a per cell
basis has been shown to be unaltered after activation of the AhR (Zhang et al., 2013), the number
of CT-specific IgA-ASCs in the intestinal LP would be predicted to be increased in TCDDtreated in the model used here.
Migration Molecules
Our data suggest differential regulation of a4b7 integrin and CCR9 expression in vitro in
the presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Given that both a4b7 integrin and CCR9
are critical for gut-homing, it was predicted that there would be a substantial increase in surface
expression of a4b7 integrin and CCR9 in the presence of TCDD. Considering the significance of
the a4 integrin being present, analyzing expression of a4 integrin in this model would provide
further insight into the distinctive surface expression between a4b7 and b7 integrin we observed.
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In addition, b1 integrin dimerizes with a4 integrin. Although a4b1 integrin is associated with
trafficking to other nonintestinal mucosal tissues as well as inflamed tissues (Kang et al., 2011),
it would be interesting to discover upregulation of b1 integrin in our model, as this would
suggest an AhR-mediated effect on the migration of B cells to gut-associated lymphoid tissues in
addition to other nonintestinal mucosal locations. Because binding of a4b7 integrin to
MAdCAM-1 is enhanced in the presence of CCL25 (Sun et al., 2014), expressed by IECs of the
small intestine (Pabst et al., 2004), it would be of interest to determine the influence of AhR
activation on CCL25. Based on our findings of increased levels of CCR9 expression following
TCDD exposure in vitro, we would predict that this would be paralleled with increased levels of
CCL25 in vivo, thereby promoting B cell migration into the small intestine through upregulation
of CCR9 and its respective ligand, CCL25, allowing for the activation of a4b7 integrin.
We investigated the influence of exposure to aryl hydrocarbon receptor ligands on CD19+
spleen cells in vitro. Using our in vivo model, we would predict enhanced expression of a4b7
integrin and CCR9 on plasma cells within the LP from TCDD treated and CT-immunized mice
when compared to immunized mice only. We would further hypothesize that comparable
expression levels of a4b7 integrin and CCR9 on CD19+ splenocytes would be observed between
TCDD-treated, CT-immunized and CT-immunized mice by the experimental endpoint due to
ASC migration occurring at an earlier time point, as suggested by our findings of significant
reductions in IgA-ASC quantities in the spleen at the experimental endpoint.
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Time-Course and Dose-Response
Studies
2,3,7,8-Tetrachlorodibenzo-p-dioxin
Exposure Following Activation of
CD19+ Splenocytes
In our model, CD19+ spleen cells were stimulated in the presence of AhR ligands. It
would be of interest to determine the influence of TCDD exposure on CD19+ spleen cells that
were activated prior to TCDD exposure, to examine the influence of AhR activity on the
migration of activated B cells. Several proteins involved in B cell activation and differentiation
have been shown to be suppressed by AhR activation (De Abrew et al., 2010; Schneider et al.,
2009). It is possible that activated and class switched CD19+ cells would have altered sensitivity
to AhR-mediated effects, as Chastain and Pazdernik (1985) found that splenic B cells were less
sensitive to TCDD exposure compared to B cells in the bone marrow which contains immature B
cells. Alternatively, because the expression of a4b7 integrin and CCR9 has been shown to be
increased by the addition of retinoic acid on both, naïve and activated B cells (Mora et al., 2006),
exposure to TCDD would be hypothesized to comparably enhance the expression of a4b7
integrin and CCR9 when added before or after activation of CD19+ splenocytes.
Dose-Dependent Competition
Between 2,3,7,8-Tetra-chlorodibenzo-p-dioxin and 2methyl-2H-pyrazole-3carboxylic acid (2methyl-4-o-tolyazo-phenyl)amide
Our data show that CD19+ cells activated in the presence of the AhR with the antagonist,
CH-223191, have significantly reduced percentages of cells expressing the gut-homing markers
analyzed here. These observations are additionally observed when CD19+ cells are activated in
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the presence of both, CH-223191 and TCDD. It is of interest to determine if the significant
reductions in the percentages of cells expressing the gut-homing markers analyzed here would be
observed using alternative dosages of CH-223191 and TCDD. Because CH-223191 has been
shown to inhibit TCDD-mediated nuclear translocation of the AhR in a dose-dependent manner
in hepatocytes (Kim et al., 2006), we would hypothesize that similar dose-dependent reductions
on the expression of gut-homing markers on CD19+ splenocytes exposed to CH-223191 would
be observed in our model. The dosage by which TCDD would outcompete CH-223191 and
promote upregulated expression of gut migration markers on CD19+ splenocytes requires
characterization in our model. Determining the level of competition between TCDD and CH223191 in our model would provide further insight into the level at which AhR activation
positively contributes to B cell gut-homing.
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Date:
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Principal Investigator:

Greg Dekrey

Committee Action:
Action Date:

IACUC Protocol- Annual Continuation Approval #2- 2020
September 29, 2020

Protocol Number:
Protocol Title:

1812C-GD-M-21
TCDD exposure alters mucosal immunity by enhancing IgA secretion into the gut
lumen

Expiration Date:

December 13, 2021

The University of Northern Colorado Institutional Animal Care and Use Committee (IACUC) has completed an
annual review and APPROVED the continuation of animal use protocol TCDD exposure alters mucosal
immunity by enhancing IgA secretion into the gut lumen – #1812C-GD-M-21 on September 29, 2020 for
another year. Since no changes were incorporated into this protocol at this time, animal use may continue for
another year as previously approved.
The committee’s review was based on the requirements of the Government Principles, Public Health Policy,
USDA Animal Welfare Act and Regulations, the Guide for the Care and Use of Laboratory Animals, as well as
university policies and procedures related to the care and use of animals at the UNC. Based on the review, the
IACUC has determined that all review criteria have been adequately addressed. The PI is approved to perform
the experiments or procedures as described in the protocol as approved by the committee for another year. It is
the responsibility of the PI to be familiar with and comply with the protocol and all pertinent institutional, state,
and federal rules and policies. Until this protocol expires, annual IACUC review of the protocol is required.
If you have any questions, please contact the UNC Animal Care and Use Program (ACUP) Director, Laura
Martin, at 734-730-6631 or via e-mail at laura.martin@unco.edu. Additional information concerning the
requirements for the welfare and use of animal subjects can be found at the websites for the University of Northern
Colorado ACUP https://www.unco.edu/research/research-integrity-and-compliance/iacuc/, the NIH’s Office of
Laboratory Animal Welfare https://olaw.nih.gov/, and the USDA’s Animal Plant and Health Inspection Services
https://www.aphis.usda.gov/aphis/home/.
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Laura W. Martin
Director of Compliance and Operations
Animal Care and Use Program
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